# Patent

## Title
Catalyst for synthesizing polyolefins

## Abstract

The present invention relates to a method for producing a high-molecular-weight copolymer of polar group-containing allyl monomers comprising monomer units represented by formulae (3) and (4) (in the formulae, R1 represents a hydrogen atom (H) or hydrocarbon group having 1 to 6 carbon atoms; R2 represents —OH, —OCOR3 (R3 represents hydrocarbon group having 1 to 5 carbon atoms), —N(R4)2 (R4 represents a hydrogen atom or hydrocarbon group having 1 to 5 carbon atoms); and n and m are a value representing the molar ratio of each of the monomer units), which has few branches and unsaturated group at the molecular end, by copolymerizing olefin and an allyl compound using a metal complex of group 10 elements in the periodic system represented by formula (I) as a catalyst.
The present invention enables providing a high-molecular-weight copolymer of polar group-containing allyl monomers, which copolymer has a novel structure, is available for various applications and has been considered to be difficult to synthesize by other polymerization methods such as radical polymerization; and a method for producing the same.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2013/062538, filed on Apr. 30, 2013, which claims priority from Japanese Patent Application No. 2012-109876, filed on May 11, 2012, and Japanese Patent Application No. 2013-041528, filed on Mar. 4, 2013, the contents of all of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present invention relates to a novel organometallic compound; a method for producing the same; a catalyst for synthesizing polyolefins (a catalyst compound for polymerization of vinyl monomers and for copolymerization of non-polar olefins and polar olefins); and a method for producing a (co)polymer using the catalyst.
BACKGROUND ART
Although polyolefins typified by polyethylene and polypropylene have been used versatilely, they are not suitable for all uses. Polyolefins are inherently non-polar, and therefore inferior in the properties such as adhesiveness, and persistence, print performance and affinity of dyes, and limited in their usefulness. However, it is known that such properties can be remarkably improved in functionalized polyolefins obtained by incorporating a small amount of polar functional groups in polyolefins.
In an effort to expand the application range of polyolefins, methods for incorporating polar functional groups into polyolefins have been reported (Non-patent documents 1, 2 and the like). Among these methods, the most direct method is to copolymerize olefin monomers with industrially useful polar vinyl monomers as shown in the following formula.




Coordination-insertion polymerization (coordination-addition polymerization) of olefins and polar vinyl monomers using a transition metal catalyst was proposed as a useful method for synthesizing functionalized polyolefins having a predetermined polymer structure, molecular weight distribution and amount of comonomer to be incorporated. As a late transition metal complex as a catalyst for coordination-insertion polymerization of olefins and polar vinyl monomers, the most successful one to date is the catalyst in which α-diimine or phosphine sulfonate ion is coordinated (Patent Document 1, Non-patent Documents 3 and 4). Generally, a highly-linear microstructure of polymer can be obtained by a palladium and nickel catalyst in which a phosphine-sulfonate ion is coordinated. Meanwhile, a palladium and nickel catalyst in which α-diimine is coordinated serves as a catalyst for forming a highly-branched polymer. Among these two important catalysts, it has been reported that the catalyst in which a phosphine-sulfonate ion is coordinated exhibits much higher activity in the copolymerization with polar vinyl monomers such as vinyl acetate, acrylonitrile, vinyl chloride and vinyl ether, compared to the catalyst in which α-diimine is coordinated (Non-patent Documents 5, 6 and the like).
However, a transition metal complex in which phosphine-sulfonate ion is coordinated has not yet been put to practical use.
Also, a method for copolymerizing ethylene and methyl acrylate using a nickel complex having an iminoamide ligand has been proposed (Patent Document 2), but the method has not yet been put to practical use, either.
PRIOR ART
Patent Document


    Patent Document 1: U.S. Pat. No. 4,689,437
    Patent Document 2: JP-A-2010-265386


Non-Patent Document


    Non-patent Document 1: Chem. Rev., 2006, 250, 47
    Non-patent Document 2: Prog. Polym. Sci., 1989, 14, 811
    Non-patent Document 3: J. Am. Chem. Soc., 1996, 118, 267
    Non-patent Document 4: Chem. Commun., 2002, 744
    Non-patent Document 5: J. Am. Chem. Soc., 2009, 131, 14606-14607
    Non-patent Document 6: J. Am. Chem. Soc., 2007, 129, 8948


SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
An object of the present invention is to provide a catalyst composition for polymerizing polyolefins, which composition contains a novel organometallic compound and has higher activity than a conventional transition metal complex in which a phosphine-sulfonate ion is coordinated.
Method to Solve the Problem
A critical structural feature of a catalyst containing phosphine-sulfonate ester is that there exist one strong σ-donor ligand and one weak σ-donor ligand. To date, a catalyst having high activity in copolymerization of olefins and various polar monomers has been limited to a phosphine-sulfonate ester type. The present inventors thought that a complex containing a bidentate ligand having an asymmetry structure of a strong σ-donor ligand and one weak σ-donor ligand other than the combination of phosphine and sulfonate ester anion can promote formation of a highly-linear random copolymer in the coordination-insertion polymerization, and have studied various bidentate ligands. As a result, the present inventors have found that a novel cationic palladium complex to which bisphosphine monoxide (BPMO) is coordinated is applicable to a catalyst for polymerization of ethylene and a number of polar vinyl monomers and accomplished the present invention.
That is, the present invention relates to an organometallic compound described in [1] to [21] below, a catalyst composition for (co)polymerization described in [22] to [23] below, a method for producing copolymers described in [24] to [26] below, and a method for producing an organometallic compound described in [27] to [28] below.
[1] An organometallic compound containing bisphosphine monoxide (BPMO) represented by formula (I) and a metal center M comprising elements belonging to Group 10 in the periodic system forming a complex with BPMO




(in the formula, R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure; and A1 represents an arylene group, a monocyclic heteroarylene group, bivalent heterocyclic group, alkylene group having 1 to 2 carbon atoms, cycloalkylene group having 3 to 10 carbon atoms, alkenylene group having 2 to 8 carbon group, or cycloalkenylene group having 3 to 10 carbon atoms).

[2] The organometallic compound as described in [1] above, represented by formula (II)





(in the formula, M, R1a, R1b, R2a, R2b and A1 have the same meanings as in [1] above; and R3 represents a hydrogen atom, alkyl group having 1 to 10 carbon atoms, alkenyl group having 2 to 10 carbon atoms or bivalent group represented by A2 (A2 represents arylene group, monocyclic heteroarylene group, monocyclic cycloalkylene group, monocyclic cycloalkenylene group, monocyclic heterocycloalkylene group, monocyclic heterocycloalkenylene group, heterocyclic group or C2-C4 alkylene group); R4 represents a neutral electron-donating ligand; R3 and R4 may be crosslinked; when R3 and R4 are crosslinked, L represents a single bond or a bivalent group selected from alkylene group, haloalkylene group, alkenylene group and alkynilene group; and when R3 and R4 are not crosslinked (that is, when L does not exist), R4 needs not to exist; and X− represents a counterion of the cationic organometallic compound).

[3] The organometallic compound as described in [2] above, wherein ligand R4 is:

(i) selected from pyridine, substituted pyridine, a nitrile compound, ammonia, alkylamine, substituted alkylamine, arylamine and substituted arylamine; or

(ii) represented by formula (1)





(in the formula, W represents C or S; Z is selected from O, S, NH or NRa (Ra represents alkyl group or aryl group) and Y needs not to exist; when Y exists, Y is selected from O, S, NH or NRb (Rb represents alkyl group or aryl group); R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, —ORc (Rc represents alkyl group or aryl group) or —NRd2 (Rd represents alkyl group or aryl group)).

[4] The organometallic compound as described in any one of [1] to [3] above represented by formula (III)





(in the formula, M, R1a, R1b, R2a, R2b, A1 and X− have the same meanings as in formula (I) in [1] above and formula (II) in [2] above; R6 represents alkyl group having 1 to 10 carbon atoms, alkenyl group or aryl group; R7, R8 and R9 independently represent alkyl group or alkoxy group having 1 to 4 carbon atoms).

[5] The organometallic compound as described in any one of [1] to [3], represented by formula (IIa)





(in the formula, M, R1a, R1b, R2a, R2b, R6, A1 and X− have the same meanings as in [1] to [3] above).

[6] The organometallic compound as described in [4] or [5] above, wherein A1 is substituted or unsubstituted phenylene group, substituted or unsubstituted naphthylene group or substituted or unsubstituted methylene group.

[7] The organometallic compound as described in any one of [4] to [6] above, wherein R1a, R1b, R2a and R2b independently represent branched alkyl group having 3 to 6 carbon atoms.

[8] The organometallic compound as described in any one of [1] to [7] above, wherein both of R1a and R1b are isopropyl group or t-butyl group.

[9] The organometallic compound as described in any one of [1] to [8] above, wherein both of R2a and R2b are t-butyl group.

[10] The organometallic compound as described in any one of [4] to [9] above, wherein X− is selected from SbF6—, BPh4-, BArF4— (ArF4—═[3,5-(CF3)2C6H3]4—), BF4— and PF6—.

[11] The organometallic compound as described in any one of [4] to [10] above, wherein M is palladium.

[12] The organometallic compound as described in any one of [1] to [3] above, represented by formula (IV)





(in the formula, M, R1a, R1b, R2a, R2b, R5, A1, A2, Y, Z, W and X− have the same meanings as in [1] to [3] above).

[13] The organometallic compound as described in [12] above, wherein A1 is a substituted or unsubstituted phenylene group, a substituted or unsubstituted naphthylene group or a substituted or unsubstituted methylene group.

[14] The organometallic compound as described in [12] or [13] above, represented by formula (V)





(in the formula, M, R1a, R1b, R2a, R2b, A2, R5 and X− have the same meanings as in [1] to [3] above; R11 may not exist or represents alkyl group having 1 to 10 carbon atoms, 1 to 4 of which exist on a benzene ring, and the existing two or more R11's may be the same or different with each other).

[15] The organometallic compound as described in [14] above, wherein A2 is substituted or unsubstituted phenylene group or naphthylene group.

[16] The organometallic compound as described in [15] above, represented by formula (VI)





(in the formula, M, R1a, R1b, R2a, R2b, R5, R11 and X− have the same meanings as in [1] to [3] and [14] above).

[17] The organometallic compound as described in any one of [12] to [16] above, wherein R1a, R1b, R2a and R2b are independently branched alkyl group having 3 to 14 carbon atoms.

[18] The organometallic compound as described in any one of [12] to [17] above, wherein both of R1a and R1b are isopropyl group.

[19] The organometallic compound as described in any one of [12] to [18] above, wherein both of R2a and R2b are t-butyl group.

[20] The organometallic compound as described in any one of [12] to [19] above, wherein X− is selected from SbF6−, BPh4−, BArF4−, BF4− and PF6−.

[21] The organometallic compound as described in any one of [12] to [20] above, wherein M is palladium.

[22] A catalyst composition for polymerizing vinyl monomers, which contains the organometallic compound described in any one of [1] to [21] above.

[23] A catalyst composition for copolymerizing non-polar olefins and polar olefins, which contains the organometallic compound described in any one of [1] to [21] above.

[24] A method for producing copolymers, comprising a process of reacting non-polar olefins with polar olefins under polymerization conditions in the presence of the catalyst composition containing the organometallic compound described in any one of [1] to [21] above.

[25] The method for producing copolymers as described in [24] above, wherein polar olefins are represented by formula (VII)

CH2═CR13R14  (VII)

(in the formula, R13 represents a hydrogen atom or methyl group; R14 represents —COOR15, —CN, —OCOR15, —OR15, —CH2—OCOR15, —CH2OH, —CH2—N(R16)2 or —CH2-Hal (R15 represents a hydrogen atom, alkyl group having 1 to 5 carbon atoms or aryl group having 6 to 18 carbon atoms; R16 represents a hydrogen atom, alkyl group having 1 to 5 carbon atoms, aryl group having 6 to 18 carbon atoms or alkoxycarbonyl group; and Hal represents a halogen atom)).

[26] The method for producing copolymers as described in [25] above, wherein R14 is —CH2—OCOR15, —CH2OH, —CH2—N(R16)2 or —CH2-Hal (R15, R16 and Hal have the same meanings as described in [25] above).

[27] A method for producing an organometallic compound represented by formula (III)





(in the formula, M, R1a, R1b, R2a, R2b, R6, R7, R8, R9, A1 and X have the meanings as set forth below), comprising:

    (1) A process of reacting free bisphosphine monoxide (BPMO) represented by formula (I)






(in the formula, R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure; and A1 represents an arylene group, a monocyclic heteroarylene group, heterocyclic group, alkylene group having 1 to 2 carbon atoms, cycloalkylene group having 3 to 10 carbon atoms, alkenylene group having 2 to 8 carbon group, or cycloalkenylene group having 3 to 10 carbon atoms) and (1,5-cyclooctadiene) MR6Xa (M represents an element belonging to Group 10 in the periodic system; R6 represents alkyl group having 1 to 10 carbon atoms, alkenyl group or aryl group; and Xa represents a halogen atom); and

    (2) A process of treating the generated (BPMO)(1,5-cyclooctadiene) MR6Xa complex with a metal salt represented by M2X (M2 represents a monovalent metal ion selected from Ag, Li, Na and K; and X represents a counteranion selected from SbF6, BPh4, BArF4, BF4 and PF6) and a compound represented by formula (2)






(in the formula, R7, R8 and R9 independently represent a hydrogen atom, alkyl group having 1 to 4 carbon atoms or alkoxy group).

[28] A method for producing an organometallic compound represented by formula (IVa)





(in the formula, M, R1a, R1b, R2a, R2b, R5, A1, A2 and X have the meanings as set forth below), comprising:

    (1) A process of reacting free bisphosphine monoxide (BPMO) represented by formula (I)






(in the formula, R1a, R1b, R2a, R2b and A1 have the meanings as described in [1] above) with a compound represented by formula (3)





(in the formula, M represents an element belonging to Group 10 in the periodic system; A2 represents an arylene group, a monocyclic heteroarylene group, a monocyclic cycloalkylene group, a monocyclic cycloalkenylene group, a monocyclic heterocycloalkylene group, a monocyclic heterocycloalkenylene group, heterocyclic or C2-C4 alkylene group; R5 represents substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, ORc (Rc represents alkyl group or aryl group) or NRd2 (Rd represents alkyl group or aryl group); and Xb represents halogen); and

    (2) a process of adding a metal salt represented by M2X (M2 represents a monovalent metal ion selected from Ag, Li, Na and K; and X represents a counteranion selected from SbF6, BPh4, BArF4, BF4 and PF6) to the reaction product of process (1).


Effects of the Invention
The catalyst composition containing a novel organometallic compound of the present invention has a high activity in the coordination-insertion polymerization of ethylene and polar vinyl monomers. By using the catalyst composition of the present invention, a highly-linear polymer can be obtained and further, a copolymer in which polar monomers are randomly distributed in polymer chains can be obtained. Thus, the catalyst composition containing a novel organometallic compound of the present invention is extremely useful since it enables the production of industrially-useful functionalized polyolefin.



BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 13C-NMR chart of the product of Example 5
FIG. 2 13C-NMR chart of the product of Example 10
FIG. 3 13C-NMR chart of the product of Example 12
FIG. 4 13C-NMR chart of the product of Example 14
FIG. 5 13C-NMR chart of the product of Example 16
FIG. 6 13C-NMR chart of the product of Example 18



MODE FOR CARRYING OUT THE INVENTION
The organometallic compound of the present invention is a compound comprising a complex formed by bisphosphine monoxide (BPMO) represented by formula (I) as a ligand with metal center M composed of an element belonging to Group 10 in the periodic system.




Here, M represents an element belonging to Group 10 in the periodic system.
In formula (I), R1a, R1b, R2a, and R2b may be the same or different with each other and independently represent substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, substituted or unsubstituted biphenyl group (C6H5—C6H4—) or substituted or unsubstituted aryl group; and preferably substituted or unsubstituted alkyl group having 1 to 14 carbon atoms.
Also, a pair of R1a and R1b and a pair of R2a and R2b may be bonded and form a ring structure.
Specific examples of the [(R1a)(R1b)P] and [(R2a)(R2b)P] sites include the following structures. In the following structure formulae, the bonds between P and O, and P and A1 are omitted.













A1 represents an arylene group, a monocyclic heteroarylene group, bivalent heterocyclic group, alkylene group having 1 to 2 carbon atoms, cycloalkylene group having 3 to 10 carbon atoms, alkenylene group having 2 to 8 carbon group, or cycloalkenylene group having 3 to 10 carbon atoms. Examples of A1 include ortho-phenylene group, 1,2-naphthylene group, 1,8-naphthylene group, 1,2-cyclohexylene group, 1,2-cyclopentylene group, 1,2-vinylene group, 1,2-cyclohexenylene group, 1,2-cyclopentenylene group, methylene group, and ethylene group which is unsubstituted or in which alkyl group, alkoxy group, amino group or ester group may be substituted. From the viewpoint of the ease of synthesis, ortho-phenylene group, 1,2-naphthylene group, 1,8-naphthylene group and methylene group are preferable, and ortho-phenylene group and methylene group are more preferable.
One embodiment of the present invention is an organometallic compound represented by formula (II).




In formula (II), M, R1a, R1b, R2a, R2b and A1 have the meanings as described above.
R3 represents alkyl group having 1 to 10 carbon atoms, alkenyl group having 1 to 10 carbon atoms or bivalent group represented by A2; and A2 represents arylene group, monocyclic heteroarylene group, monocyclic cycloalkylene group, monocyclic cycloalkenylene group, monocyclic heterocycloalkylene group, monocyclic heterocycloalkenylene group, or heterocyclic or C2-C4 alkylene group.
R4 represents a neutral electron-donating ligand. Examples of a neutral electron-donating ligand include pyridine, substituted pyridine, quinoline, substituted quinoline, nitrile compounds, ammonia, alkylamine, substituted alkylamine, arylamine, substituted arylamine, sulfoxide, alkylphosphine, substituted alkylphosphine, arylphosphine, substituted arylphosphine, alkyl phosphite, substituted alkyl phosphite, aryl phosphite, substituted aryl phosphite, aliphatic ether, substituted aliphatic ether, cyclic ether, and substituted cyclic ether. Specifically, pyridine, 2,6-dimethylpyridine, 4-(N,N-dimethylamino)pyridine (DMAP); quinoline, 2-methylquinoline; trialkylamine having 1 to 10 carbon atoms, N,N,N′,N′-tetramethylethylenediamine (TMEDA); dialkylaminoaniline, 2,6-dimethylaniline, 2,6-diisopropylaniline, acetonitrile, benzonitrile; dimethylsulfoxide (DMSO); trimethylphosphine, triisopropylphosphine, tributylphosphine, tri(t-butyl)phosphine, triphenylphosphine, tris(o-tolyl)phosphine, trifurylphosphine; diethyl ether; tetrahydrofuran, 1,4-dioxane; and 1,2-dimethoxyethane.
In another embodiment of the present invention, R4 is selected from pyridine, substituted pyridine, nitrile compounds, ammonia, alkylamine, substituted alkylamine, arylamine and substituted arylamine; and preferably pyridine or substituted pyridine.
In another embodiment of the present invention, ligand R4 is represented by formula (1).




In formula (1), W represents a carbon atom (C) or a sulfur atom (S), Z is selected from an oxygen atom (O), S, NH or NRa (Ra represents alkyl group or aryl group); Y is selected from O, S, NH or NRb (Rb represents alkyl group or aryl group); R5 is substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, ORc (Rc represents alkyl group or aryl group) or NRd2 (Rd represents alkyl group or aryl group).
R3 and R4 may be crosslinked, and when R3 and R4 are crosslinked, L represents a single bond or bivalent group selected from alkylene group, haloalkylene group, alkenylene group and alkynylene group. When R3 and R4 are not crosslinked, L does not exist.
R4 needs not exist. When R4 does not exist, the embodiment of the organometallic compound represented by formula (II) becomes the threefold-coordination organometallic compound represented by formula (IIa).




In the formula, M, R1a, R1b, R2a, R2b and A1 have the meanings as described above.
X− represents a counterion of the cationic organometallic complex. The counterion represented by X− may be any monovalent anion. Further, if the charge number per atom of the metal center (M) is monovalent, X− may be a polyvalent anion. Specifically, examples include sulfate ion (SO42−), nitrate ion (NO3−), carbonate ion (CO32−), perchlorate ion (ClO4−), halide ion such as chloride ion (Cl−), bromide ion (Br−) and iodide ion (I−); borate ion such as tetrafluoroborate (BF4−), bromotrifluoroborate (BBrF3−), chlorotrifluoroborate (BClF3−), trifluoromethoxyborate (BF3(OCH3)−), trifluoroethoxyborate (BF3(OC2H5)−), trifluoroallyloxyborate (BF3(OC3H5)−), tetraphenylborate (B(C6H5)4−), tetrakis(3,5-bis(trifluoromethyl)phenyl)borate (B(3,5-(CF3)2C6H3)4−=BArF4−), bromotriphenylborate (BBr(C6H5)3−), chlorotriphenylborate (BCl(C6H5)3−), methoxytriphenylborate (B(OCH3)(C6H5)3−), ethoxytriphenylborate (B(OC2H5)(C6H5)3−), allyloxytriphenylborate (B(OC3H5)(C6H5)3−), tetrakis(pentafluorophenyl)borate (B(C6F5)4−), bromotris(pentafluorophenyl)borate (BBr(C6F5)3−), chlorotris(pentafluorophenyl)borate (BCl(C6F5)3−), methoxytris(pentafluorophenyl)borate (B(OCH3)(C6H5)3−), ethoxytris(pentafluorophenyl)borate (B(OC2H5)(C6F5)3−) and allyloxytris(pentafluorophenyl)borate (B(OC3H5)(C6F5)3−); sulfonate ion such as methanesulfonate ion (CH3SO3−), trifluoromethanesulfonate (CF3SO3−), nonafluorobutanesulfonate (C4F9SO3−), benzenesulfonate (C6H5SO3−) and p-toluenesulfonate (p-CH3—C6H4SO3−); carboxylate ion such as acetate ion (CH3CO2−), trifluoroacetate ion (CF3CO2−), trichloroacetate ion (CCl3CO2−), propionate ion (C2H5CO2—) and benzoate ion (C6H5CO2−); phosphate ion such as hexafluorophosphate ion (PF6−); arsenate ion such as hexafluoroarsenate ion (AsF6−); antimonate ion such as hexafluoroantimonate (SbF6−); and silicate ion such as hexafluorosilicate (SiF6−). Among these counterions, preferred are those in which X− is SbF6−, BPh4−, BArF4−, BF4− and PF6−.
Among the organometallic compounds represented by formula (II) of the present invention, a preferred embodiment is an organometallic compound represented by formula (III).




In formula (III), M, R1a, R1b, R2a, R2b, A1 and X− have the meanings as described above.
R6 represents an alkyl group, alkenyl group or aryl group, which has 1 to 10 carbon atoms.
R7, R8 and R9 independently represent a hydrogen atom, or alkyl group or alkoxy group, which has 1 to 4 carbon atoms.
In formula (III), A1 is preferably a substituted or unsubstituted phenylene group, substituted or unsubstituted naphthylene group, or substituted or unsubstituted methylene group.
Among the organometallic compounds represented by formula (III) of the present invention, a preferred embodiment is an organometallic compound represented by the following formula (IIIa).




Here, M, R1a, R1b, R2a, R2b, R7, R8, R9 and X− have the meanings as described above.
R10 does not exist, or represents an alkyl group having 1 to 10 carbon atoms, which is substituted with an arbitrary replaceable hydrogen in a benzene ring, and when two or more R10's exist, they may be the same or different with each other.
Meanwhile, an organometallic compound represented by formula (IIIc) is a preferred embodiment among the organometallic compounds represented by formula (III) as well.




In the formula, R1a, R1b, R2a, R2b, R7, R8, R9 and X− have the meanings as described above.
R13a and R13b independently represent a hydrogen atom, alkyl group having 1 to 10 carbon atoms or aryl group having 6 to 12 carbon atoms, and may be the same or different with each other. R13a and R13b may bond to each other to form a crosslinked structure.
In formulae (III), (IIIa) or (IIIc), R1a, R1b, R2a and R2b, independently from each other, are preferably a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, and more preferably, a branched alkyl group having 3 to 5 carbon atoms. In a conventional transition metal complex to which phosphine-sulfonate is coordinated, an aryl group have been used as a substituent of a phosphorus atom. In a novel organometallic compound of the present invention to which bisphosphine monoxide (BPMO) is coordinated, it was found that the compound exhibited higher activity in polymerization of olefins when an alkyl group was used as a substituent of a phosphorus atom than the case where an aryl group was used.
In the present invention, it is especially preferable that R1a, R1b, R2a and R2b in formula (III) are an isopropyl group or t-butyl group, independently from each other. It is particularly preferable that R1a and R1b are an isopropyl group and R2a and R2b are a t-butyl group.
In an embodiment where the organometallic compound of the present invention is a compound represented by formula (IIIc), both of R13a and R13b in formula (IIIc) are preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
In formula (III), M is an element belonging to Group 10 in the periodic system, preferably nickel or palladium, and more preferably, palladium.
Among the organometallic compounds represented by formula (II) of the present invention, another preferred embodiment is an organometallic compound represented by formula (IV).




In formula (IV), M, R1a, R1b, R2a, R2b, A1 and X− have the meanings as described above.
In the organometallic compound of formula (IV), the portion represented by formula (1) forms a closed ring structure within a molecule. Here, a conventional transition metal complex to which phosphine-sulfonate is coordinated was stabilized using strong Lewis base such as pyridine, but it tended to inhibit vinyl monomer from inserting/coordinating to the metal. In the novel organometallic compound represented by formula (IV), introducing weak Lewis base as “Z” can stabilize the complex by forming a closed ring structure within a molecule, as well as facilitate the insertion/coordination of the vinyl monomer to the metal.
Here, as defined in formula (1), W represents C or S; Z is selected from O, S, NH or NRa (Ra represents alkyl group or aryl group) and when Y exists, Y is selected from O, S, NH or NRb (Rb represents alkyl group or aryl group); R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, ORc (Rc represents alkyl group or aryl group), NRd2 or SRd (Rd represents alkyl group or aryl group). When Y does not exist, W is directly bonded to A2. Specific examples of ligands represented by YW(═Z)R5 (1) include OC(═O)R, OC(═O)OR, NHC(═O)R, NHC(═O)OR, C(═O)OR, OC(═S)R, OC(═S)SR, C(═O)NHR, C(═O)N(R)2 and OS(═O)OR(R represents an alkyl or aryl group, and when two R's exist, they may be the same or different).
In one preferred embodiment of the present invention, the organometallic compound is represented by formula (IVa) in which the ligand represented by YW(═Z)R5 (1) is NH(C═O)R5.




In the formula, M, R1a, R1b, R2a, R2b, R5, A1, A2 and X− have the same meanings as described above.
A2 represents arylene group, monocyclic heteroarylene group, monocyclic cycloalkylene group, monocyclic cycloalkenylene group, monocyclic heterocycloalkylene group, monocyclic heterocycloalkenylene group, heterocyclic group or C2-C4 alkylene group. Specifically, examples of A2 include o-phenylene group, 1,2-naphthylene group, 1,8-naphthylene group, 1,2-cyclohexylene group, 1,2-cyclopentylene group; ethylene group (—CH2—CH2—), propylene group (—CH2—CH2—CH2—) and butylene group (—CH2—CH2—CH2—CH2—) group, which are unsubstituted, or wherein alkyl group, alkoxy group, amino group, ester group may be substituted.
In formula (IV), A1 represents arylene group, monocyclic heteroarylene group, heterocyclic group, alkylene group having 1 to 2 carbon atoms, cycloalkylene group having 3 to 10 carbon atoms, alkenylene group having 2 to 8 carbon atoms, or cycloalkenylene group having 3 to 10 carbon atoms. Preferred are substituted or unsubstituted phenylene group, substituted or unsubstituted naphthylene group, or substituted or unsubstituted methylene group.
Among the organometallic compounds represented by formula (IV) of the present invention, one preferred embodiment is an organometallic compound represented by formula (V).




In formula (V), M, R1a, R1b, R2a, R2b, A2, R5 and X− have the same meanings as described above.
R11 does not exist, or represents an alkyl group having 1 to 10 carbon atoms, which is substituted with an arbitrary replaceable hydrogen in a benzene ring, and when two or more R11's exist, they may be the same or different with each other.
In formula (V), A2 represents arylene group, monocyclic heteroarylene group, monocyclic cycloalkylene group, monocyclic cycloalkenylene group, monocyclic heterocycloalkylene group, monocyclic heterocycloalkenylene group, or heterocyclic or C2-C4 alkylene group. Preferred are substituted or unsubstituted phenylene group and substituted or unsubstituted naphthylene group.
Among the organometallic compounds represented by formula (IV) of the present invention, another preferred embodiment is the organometallic compound represented by the following formula (VI).




In formula (VI), M, R1a, R1b, R2a, R2b, R5, R11 and X− have the same meanings as described above.
R12 does not exist, or represents an alkyl group having 1 to 10 carbon atoms, which is substituted with an arbitrary replaceable hydrogen in a benzene ring, and when two or more R12's exist, they may be the same or different with each other.
In formulae (IV) to (VI), R1a, R1b, R2a and R2b, independently from each other, are preferably substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, more preferably a branched alkyl group having 3 to 5 carbon atoms. It is preferable that R1a, R1b, R2a and R2b are an isopropyl group or t-butyl group, independently from each other. It is particularly preferable that R1a and R1b are an isopropyl group and R2a and R2b are a t-butyl group.
In formulae (IV) to (VI), M is an element belonging to Group 10 in the periodic system and preferably nickel or palladium, more preferably, palladium.
An example of the organometallic compounds represented by formula (III) of the present invention, wherein A1 is phenylene, can be synthesized, for example, by the following scheme 1.




The compound can be obtained by, after mixing free bisphosphine monoxide (BPMO) and (cod)PdMeCl (cod=1,5-cyclooctadiene), treating the intermediate (BPMO)(cod)PdMeCl complex with silver hexafluoroantimonate and 2,6-lutidine.
Specific examples of the organometallic compounds represented by formulae (II) to (VI) of the present invention are described below.
Regarding the case where R10 does not exist in formula (IIIa) (i.e. where there is no substituent of R10 in a benzene ring), specific examples of the organometallic compounds represented by the following formula (IIIb) of the present invention are shown in Table I.




In Table I, H represents a hydrogen atom, Me represents a methyl group, Et represents an ethyl group, n-Pr represents an n-propyl group, i-Pr represents an isopropyl group, tert-Bu represents a t-butyl group, NeoPen represents a neopentyl group, CyHex represents a cyclohexyl group, CyPen represents a cyclopentyl group, 1-Ada represents a 1-adamantyl group, and Biph represents 2′-[2,6-bis(dimethoxy)]biphenyl group. HIPT represents a group represented by the following formula.













TABLE I







Compound
R

















No.
1a
1b
2a
2b
6
7
8
9
X



















1
i-Pr
i-Pr
i-Pr
i-Pr
Me
H
H
H
SbF6


2
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
Me
H
SbF6


3
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
Me
Me
SbF6


4
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
H
Me
SbF6


5
i-Pr
tert-Bu
i-Pr
i-Pr
Me
H
H
H
SbF6


6
i-Pr
i-Pr
tert-Bu
i-Pr
Me
H
H
H
SbF6


7
i-Pr
tert-Bu
i-Pr
tert-Bu
Me
H
H
H
SbF6


8
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
H
H
H
SbF6


9
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
Me
H
SbF6


10
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
Me
Me
SbF6


11
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


12
i-Pr
i-Pr
NeoPen
NeoPen
Me
H
H
H
SbF6


13
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
SbF6


14
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
Me
Me
SbF6


15
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
SbF6


16
i-Pr
i-Pr
CyHex
CyHex
Me
H
H
H
SbF6


17
i-Pr
i-Pr
CyHex
CyHex
Me
Me
H
Me
SbF6


18
i-Pr
i-Pr
CyPen
CyPen
Me
H
H
H
SbF6


19
i-Pr
i-Pr
CyPen
CyPen
Me
Me
H
Me
SbF6


20
i-Pr
i-Pr
Me
Me
Me
H
H
H
SbF6


21
i-Pr
i-Pr
Me
Me
Me
Me
Me
H
SbF6


22
i-Pr
i-Pr
Me
Me
Me
Me
Me
Me
SbF6


23
i-Pr
i-Pr
Me
Me
Me
Me
H
Me
SbF6


24
i-Pr
i-Pr
Et
Et
Me
H
H
H
SbF6


25
i-Pr
i-Pr
Et
Et
Me
Me
H
Me
SbF6


26
i-Pr
i-Pr
n-Pr
n-Pr
Me
H
H
H
SbF6


27
i-Pr
i-Pr
n-Pr
n-Pr
Me
Me
H
Me
SbF6


28
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
H
H
H
SbF6


29
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
Me
H
SbF6


30
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
Me
Me
SbF6


31
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
SbF6


32
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
H
H
H
SbF6


33
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
Me
Me
H
SbF6


34
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
Me
Me
Me
SbF6


35
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


36
tert-Bu
tert-Bu
tert-Bu
i-Pro
Me
H
H
H
SbF6


37
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
H
H
H
SbF6


38
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
SbF6


39
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
Me
Me
SbF6


40
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
SbF6


41
tert-Bu
tert-Bu
CyHex
CyHex
Me
H
H
H
SbF6


42
tert-Bu
tert-Bu
CyHex
CyHex
Me
Me
H
Me
SbF6


43
tert-Bu
tert-Bu
CyPen
CyPen
Me
H
H
H
SbF6


44
tert-Bu
tert-Bu
CyPen
CyPen
Me
Me
H
Me
SbF6


45
tert-Bu
tert-Bu
Me
Me
Me
H
H
H
SbF6


46
tert-Bu
tert-Bu
Me
Me
Me
Me
H
Me
SbF6


47
tert-Bu
tert-Bu
Et
Et
Me
H
H
H
SbF6


48
tert-Bu
tert-Bu
Et
Et
Me
Me
H
Me
SbF6


49
tert-Bu
tert-Bu
n-Pr
n-Pr
Me
H
H
H
SbF6


50
tert-Bu
tert-Bu
n-Pr
n-Pr
Me
Me
H
Me
SbF6


51
NeoPen
NeoPen
i-Pr
i-Pr
Me
H
H
H
SbF6


52
NeoPen
NeoPen
i-Pr
i-Pr
Me
Me
H
Me
SbF6


53
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
H
H
H
SbF6


54
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


55
NeoPen
NeoPen
NeoPen
NeoPen
Me
H
H
H
SbF6


56
NeoPen
NeoPen
NeoPen
NeoPen
Me
Me
H
Me
SbF6


57
NeoPen
NeoPen
CyHex
CyHex
Me
H
H
H
SbF6


58
NeoPen
NeoPen
Me
Me
Me
Me
H
Me
SbF6


59
NeoPen
NeoPen
Et
Et
Me
Me
H
Me
SbF6


60
NeoPen
NeoPen
n-Pr
n-Pr
Me
Me
H
Me
SbF6


61
CyHex
CyHex
i-Pr
i-Pr
Me
Me
H
Me
SbF6


62
CyHex
CyHex
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


63
CyHex
CyHex
Me
Me
Me
Me
H
Me
SbF6


64
CyHex
CyHex
Et
Et
Me
Me
H
Me
SbF6


65
CyHex
CyHex
n-Pr
n-Pr
Me
Me
H
Me
SbF6


66
CyPen
CyPen
i-Pr
i-Pr
Me
Me
H
Me
SbF6


67
CyPen
CyPen
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


68
CyPen
CyPen
Me
Me
Me
Me
H
Me
SbF6


69
CyPen
CyPen
Et
Et
Me
Me
H
Me
SbF6


70
Me
Me
i-Pr
i-Pr
Me
Me
H
Me
SbF6


71
Me
Me
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


72
Me
Me
NeoPen
NeoPen
Me
Me
H
Me
SbF6


73
Me
Me
CyHex
CyHex
Me
Me
H
Me
SbF6


74
Me
Me
Et
Et
Me
Me
H
Me
SbF6


75
Me
Me
n-Pr
n-Pr
Me
Me
H
Me
SbF6


76
Et
Et
i-Pr
i-Pr
Me
Me
H
Me
SbF6


77
Et
Et
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


78
Et
Et
NeoPen
NeoPen
Me
Me
H
Me
SbF6


79
Et
Et
CyHex
CyHex
Me
Me
H
Me
SbF6


80
Et
Et
n-Pr
n-Pr
Me
Me
H
Me
SbF6


81
Et
Et
Me
Me
Me
Me
H
Me
SbF6


82
n-Pr
n-Pr
i-Pr
i-Pr
Me
Me
H
Me
SbF6


83
n-Pr
n-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


84
n-Pr
n-Pr
NeoPen
NeoPen
Me
Me
H
Me
SbF6


85
n-Pr
n-Pr
CyHex
CyHex
Me
Me
H
Me
SbF6


86
n-Pr
n-Pr
Me
Me
Me
Me
H
Me
SbF6


87
1-Ada
1-Ada
i-Pr
i-Pr
Me
Me
H
Me
SbF6


88
1-Ada
1-Ada
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


89
1-Ada
1-Ada
NeoPen
NeoPen
Me
Me
H
Me
SbF6


90
1-Ada
1-Ada
Me
Me
Me
Me
H
Me
SbF6


91
1-Ada
1-Ada
Et
Et
Me
Me
H
Me
SbF6


92
1-Ada
1-Ada
n-Pr
n-Pr
Me
Me
H
Me
SbF6


93
HIPT
HIPT
i-Pr
i-Pr
Me
Me
H
Me
SbF6


94
HIPT
HIPT
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


95
HIPT
HIPT
NeoPen
NeoPen
Me
Me
H
Me
SbF6


96
HIPT
HIPT
Me
Me
Me
Me
H
Me
SbF6


97
HIPT
HIPT
Et
Et
Me
Me
H
Me
SbF6


98
HIPT
HIPT
n-Pr
n-Pr
Me
Me
H
Me
SbF6


99
Biph
Biph
i-Pr
i-Pr
Me
Me
H
Me
SbF6


100
Biph
Biph
tert-Bu
tert-Bu
Me
Me
H
Me
SbF6


101
Biph
Biph
NeoPen
NeoPen
Me
Me
H
Me
SbF6


102
Biph
Biph
Me
Me
Me
Me
H
Me
SbF6


103
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
H
Me
BArF4


104
i-Pr
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
BArF4


105
i-Pr
i-Pr
tert-Bu
i-Pr
Me
Me
H
Me
BArF4


106
i-Pr
tert-Bu
i-Pr
tert-Bu
Me
Me
H
Me
BArF4


107
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


108
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
BArF4


109
i-Pr
i-Pr
CyHex
CyHex
Me
Me
H
Me
BArF4


110
i-Pr
i-Pr
Me
Me
Me
Me
H
Me
BArF4


111
i-Pr
i-Pr
Et
Et
Me
Me
H
Me
BArF4


112
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
BArF4


113
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


114
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
BArF4


115
tert-Bu
tert-Bu
CyHex
CyHex
Me
Me
H
Me
BArF4


116
tert-Bu
tert-Bu
Me
Me
Me
Me
H
Me
BArF4


117
tert-Bu
tert-Bu
Et
Et
Me
Me
H
Me
BArF4


118
tert-Bu
tert-Bu
n-Pr
n-Pr
Me
Me
H
Me
BArF4


119
NeoPen
NeoPen
i-Pr
i-Pr
Me
Me
H
Me
BArF4


120
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


121
NeoPen
NeoPen
NeoPen
NeoPen
Me
Me
H
Me
BArF4


122
NeoPen
NeoPen
CyHex
CyHex
Me
Me
H
Me
BArF4


123
NeoPen
NeoPen
Me
Me
Me
Me
H
Me
BArF4


124
CyHex
CyHex
i-Pr
i-Pr
Me
Me
H
Me
BArF4


125
CyHex
CyHex
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


126
CyPen
CyPen
i-Pr
i-Pr
Me
Me
H
Me
BArF4


127
CyPen
CyPen
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


128
Me
Me
i-Pr
i-Pr
Me
Me
H
Me
BArF4


129
Me
Me
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


130
Et
Et
i-Pr
i-Pr
Me
Me
H
Me
BArF4


131
Et
Et
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


132
n-Pr
n-Pr
i-Pr
i-Pr
Me
Me
H
Me
BArF4


133
n-Pr
n-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


134
1-Ada
1-Ada
i-Pr
i-Pr
Me
Me
H
Me
BArF4


135
1-Ada
1-Ada
tert-Bu
tert-Bu
Me
Me
H
Me
BArF4


136
i-Pr
i-Pr
i-Pr
i-Pr
Me
Me
H
Me
BF4


137
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
BF4


138
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
BF4


139
i-Pr
i-Pr
CyHex
CyHex
Me
Me
H
Me
BF4


140
i-Pr
i-Pr
Me
Me
Me
Me
H
Me
BF4


141
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
BF4


142
tert-Bu
tert-Bu
tert-Bu
tert-Bu
Me
Me
H
Me
BF4


143
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
BF4


144
tert-Bu
tert-Bu
CyHex
CyHex
Me
Me
H
Me
BF4


145
tert-Bu
tert-Bu
Me
Me
Me
Me
H
Me
BF4


146
NeoPen
NeoPen
i-Pr
i-Pr
Me
Me
H
Me
BF4


147
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
Me
H
Me
BF4


148
NeoPen
NeoPen
NeoPen
NeoPen
Me
Me
H
Me
BF4


149
CyHex
CyHex
i-Pr
i-Pr
Me
Me
H
Me
BF4


150
Me
Me
i-Pr
i-Pr
Me
Me
H
Me
BF4


151
Et
Et
tert-Bu
tert-Bu
Me
Me
H
Me
BF4


152
1-Ada
1-Ada
i-Pr
i-Pr
Me
Me
H
Me
BF4


153
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
PF6


154
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
PF6


155
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
PF6


156
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
PF6


157
NeoPen
NeoPen
i-Pr
i-Pr
Me
Me
H
Me
PF6


158
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
Me
H
Me
PF6


159
CyHex
CyHex
i-Pr
i-Pr
Me
Me
H
Me
PF6


160
Me
Me
i-Pr
i-Pr
Me
Me
H
Me
PF6


161
Et
Et
tert-Bu
tert-Bu
Me
Me
H
Me
PF6


162
1-Ada
1-Ada
i-Pr
i-Pr
Me
Me
H
Me
PF6


163
i-Pr
i-Pr
tert-Bu
tert-Bu
Me
Me
H
Me
ArF


164
i-Pr
i-Pr
NeoPen
NeoPen
Me
Me
H
Me
ArF


165
tert-Bu
tert-Bu
i-Pr
i-Pr
Me
Me
H
Me
ArF


166
tert-Bu
tert-Bu
NeoPen
NeoPen
Me
Me
H
Me
ArF


167
NeoPen
NeoPen
i-Pr
i-Pr
Me
Me
H
Me
ArF


168
NeoPen
NeoPen
tert-Bu
tert-Bu
Me
Me
H
Me
ArF


169
CyHex
CyHex
i-Pr
i-Pr
Me
Me
H
Me
ArF


170
Me
Me
i-Pr
i-Pr
Me
Me
H
Me
ArF


171
Et
Et
tert-Bu
tert-Bu
Me
Me
H
Me
ArF


172
1-Ada
1-Ada
i-Pr
i-Pr
Me
Me
H
Me
ArF









In the case where neither of R11 nor R12 exists in formula (VI) (i.e. there is no substituent of R11 or R12 in either of the benzene rings), specific examples of the organometallic compounds represented by the following formula (VIa) are shown in Table II.




The symbols in Table II have the same meanings as those in Table I.









TABLE II







Compound
R













No.
1a
1b
2a
2b
X





201
i-Pr
i-Pr
i-Pr
i-Pr
SbF6


202
i-Pr
tert-Bu
i-Pr
i-Pr
SbF6


203
i-Pr
i-Pr
tert-Bu
i-Pr
SbF6


204
i-Pr
tert-Bu
i-Pr
tert-Bu
SbF6


205
i-Pr
tert-Bu
tert-Bu
tert-Bu
SbF6


206
i-Pr
i-Pr
tert-Bu
tert-Bu
SbF6


207
i-Pr
i-Pr
NeoPen
NeoPen
SbF6


208
i-Pr
tert-Bu
NeoPen
NeoPen
SbF6


209
i-Pr
i-Pr
i-Pr
NeoPen
SbF6


210
i-Pr
i-Pr
CyHex
CyHex
SbF6


211
i-Pr
i-Pr
Me
Me
SbF6


212
i-Pr
i-Pr
Et
Et
SbF6


213
i-Pr
i-Pr
n-Pr
n-Pr
SbF6


214
tert-Bu
tert-Bu
i-Pr
i-Pr
SbF6


215
tert-Bu
tert-Bu
tert-Bu
tert-Bu
SbF6


216
tert-Bu
tert-Bu
tert-Bu
i-Pro
SbF6


217
tert-Bu
tert-Bu
NeoPen
NeoPen
SbF6


218
tert-Bu
tert-Bu
CyHex
CyHex
SbF6


219
tert-Bu
tert-Bu
CyPen
CyPen
SbF6


220
tert-Bu
tert-Bu
Me
Me
SbF6


221
tert-Bu
tert-Bu
Et
Et
SbF6


222
tert-Bu
tert-Bu
n-Pr
n-Pr
SbF6


223
NeoPen
NeoPen
i-Pr
i-Pr
SbF6


224
NeoPen
NeoPen
tert-Bu
tert-Bu
SbF6


225
NeoPen
NeoPen
NeoPen
NeoPen
SbF6


226
NeoPen
NeoPen
CyHex
CyHex
SbF6


227
NeoPen
NeoPen
Me
Me
SbF6


228
NeoPen
NeoPen
Et
Et
SbF6


229
NeoPen
NeoPen
n-Pr
n-Pr
SbF6


230
CyHex
CyHex
i-Pr
i-Pr
SbF6


231
CyHex
CyHex
tert-Bu
tert-Bu
SbF6


232
CyHex
CyHex
NeoPen
NeoPen
SbF6


233
CyHex
CyHex
Me
Me
SbF6


234
CyPen
CyPen
i-Pr
i-Pr
SbF6


235
CyPen
CyPen
tert-Bu
tert-Bu
SbF6


236
Me
Me
i-Pr
i-Pr
SbF6


237
Me
Me
tert-Bu
tert-Bu
SbF6


238
Me
Me
NeoPen
NeoPen
SbF6


239
Me
Me
CyHex
CyHex
SbF6


240
Et
Et
i-Pr
i-Pr
SbF6


241
Et
Et
tert-Bu
tert-Bu
SbF6


242
Et
Et
NeoPen
NeoPen
SbF6


243
Et
Et
Me
Me
SbF6


244
n-Pr
n-Pr
i-Pr
i-Pr
SbF6


245
n-Pr
n-Pr
tert-Bu
tert-Bu
SbF6


246
n-Pr
n-Pr
NeoPen
NeoPen
SbF6


247
n-Pr
n-Pr
CyHex
CyHex
SbF6


248
1-Ada
1-Ada
i-Pr
i-Pr
SbF6


249
1-Ada
1-Ada
tert-Bu
tert-Bu
SbF6


250
1-Ada
1-Ada
NeoPen
NeoPen
SbF6


251
1-Ada
1-Ada
Me
Me
SbF6


252
1-Ada
1-Ada
Et
Et
SbF6


253
HIPT
HIPT
i-Pr
i-Pr
SbF6


254
HIPT
HIPT
tert-Bu
tert-Bu
SbF6


255
HIPT
HIPT
NeoPen
NeoPen
SbF6


256
HIPT
HIPT
Me
Me
SbF6


257
Biph
Biph
i-Pr
i-Pr
SbF6


258
Biph
Biph
tert-Bu
tert-Bu
SbF6


259
Biph
Biph
NeoPen
NeoPen
SbF6


260
Biph
Biph
Me
Me
SbF6


261
i-Pr
i-Pr
i-Pr
i-Pr
BArF4


262
i-Pr
i-Pr
tert-Bu
tert-Bu
BArF4


263
i-Pr
i-Pr
NeoPen
NeoPen
BArF4


264
i-Pr
i-Pr
CyHex
CyHex
BArF4


265
i-Pr
i-Pr
Me
Me
BArF4


266
i-Pr
i-Pr
Et
Et
BArF4


267
tert-Bu
tert-Bu
i-Pr
i-Pr
BArF4


268
tert-Bu
tert-Bu
tert-Bu
tert-Bu
BArF4


269
tert-Bu
tert-Bu
NeoPen
NeoPen
BArF4


270
tert-Bu
tert-Bu
CyHex
CyHex
BArF4


271
tert-Bu
tert-Bu
Me
Me
BArF4


272
tert-Bu
tert-Bu
Et
Et
BArF4


273
tert-Bu
tert-Bu
n-Pr
n-Pr
BArF4


274
NeoPen
NeoPen
i-Pr
i-Pr
BArF4


275
NeoPen
NeoPen
tert-Bu
tert-Bu
BArF4


276
NeoPen
NeoPen
NeoPen
NeoPen
BArF4


277
NeoPen
NeoPen
CyHex
CyHex
BArF4


278
NeoPen
NeoPen
Me
Me
BArF4


279
CyHex
CyHex
i-Pr
i-Pr
BArF4


280
CyHex
CyHex
tert-Bu
tert-Bu
BArF4


281
CyPen
CyPen
i-Pr
i-Pr
BArF4


282
CyPen
CyPen
tert-Bu
tert-Bu
BArF4


283
Me
Me
i-Pr
i-Pr
BArF4


284
Me
Me
tert-Bu
tert-Bu
BArF4


285
Et
Et
i-Pr
i-Pr
BArF4


286
Et
Et
tert-Bu
tert-Bu
BArF4


287
n-Pr
n-Pr
i-Pr
i-Pr
BArF4


288
n-Pr
n-Pr
tert-Bu
tert-Bu
BArF4


289
1-Ada
1-Ada
i-Pr
i-Pr
BArF4


290
1-Ada
1-Ada
tert-Bu
tert-Bu
BArF4


291
i-Pr
i-Pr
i-Pr
i-Pr
BF4


292
i-Pr
i-Pr
tert-Bu
tert-Bu
BF4


293
i-Pr
i-Pr
NeoPen
NeoPen
BF4


294
i-Pr
i-Pr
CyHex
CyHex
BF4


295
i-Pr
i-Pr
Me
Me
BF4


296
tert-Bu
tert-Bu
i-Pr
i-Pr
BF4


297
tert-Bu
tert-Bu
tert-Bu
tert-Bu
BF4


298
tert-Bu
tert-Bu
NeoPen
NeoPen
BF4


299
tert-Bu
tert-Bu
CyHex
CyHex
BF4


300
tert-Bu
tert-Bu
Me
Me
BF4


301
NeoPen
NeoPen
i-Pr
i-Pr
BF4


302
NeoPen
NeoPen
tert-Bu
tert-Bu
BF4


303
NeoPen
NeoPen
NeoPen
NeoPen
BF4


304
CyHex
CyHex
i-Pr
i-Pr
BF4


305
Me
Me
i-Pr
i-Pr
BF4


306
Et
Et
tert-Bu
tert-Bu
BF4


307
1-Ada
1-Ada
i-Pr
i-Pr
BF4


308
i-Pr
i-Pr
tert-Bu
tert-Bu
PF6


309
i-Pr
i-Pr
NeoPen
NeoPen
PF6


310
tert-Bu
tert-Bu
i-Pr
i-Pr
PF6


311
tert-Bu
tert-Bu
NeoPen
NeoPen
PF6


312
NeoPen
NeoPen
i-Pr
i-Pr
PF6


313
NeoPen
NeoPen
tert-Bu
tert-Bu
PF6


314
CyHex
CyHex
i-Pr
i-Pr
PF6


315
Me
Me
i-Pr
i-Pr
PF6


316
Et
Et
tert-Bu
tert-Bu
PF6


317
1-Ada
1-Ada
i-Pr
i-Pr
PF6


318
i-Pr
i-Pr
tert-Bu
tert-Bu
ArF


319
i-Pr
i-Pr
NeoPen
NeoPen
ArF


320
tert-Bu
tert-Bu
i-Pr
i-Pr
ArF


321
tert-Bu
tert-Bu
NeoPen
NeoPen
ArF


322
NeoPen
NeoPen
i-Pr
i-Pr
ArF


323
NeoPen
NeoPen
tert-Bu
tert-Bu
ArF


324
CyHex
CyHex
i-Pr
i-Pr
ArF


325
Me
Me
i-Pr
i-Pr
ArF


326
Et
Et
tert-Bu
tert-Bu
ArF


327
1-Ada
1-Ada
i-Pr
i-Pr
ArF









The organometallic compounds represented by formulae (II) to (VI) of the present invention can be suitably used as a catalyst for polymerizing vinyl monomers. The catalyst composition containing the organometallic compound represented by formulae (II) to (VI) of the present invention can be used for homopolymerization of non-polar olefins, as well as copolymerization of non-polar olefins and polar olefins.
The organometallic compounds represented by formulae (II) to (VI) do not need to be isolated and the reaction solution for preparing the same can be used as it is as a catalyst composition for polymerization.
The catalyst composition of the present invention can be used for homopolymerization of non-polar olefins. Non-polar olefins are selected from, for example, α-olefins such as ethylene, propylene, 1-butene, 2-butene, isobutene, 1-pentene, 1-hexene, 1-heptene, 1-octene, 1,5-hexadiene, 1,7-octadiene, cyclopentadiene, norbornadiene; and combination thereof. Suitable non-polar olefin may be ethylene.
The catalyst composition of the present invention can be used for copolymerization of the above-mentioned non-polar olefins and polar olefins. The polar olefins to be used is at least one member selected from the group consisting of vinyl ester such as vinyl formate, vinyl acetate, vinyl n-propionate, vinyl butyrate, vinyl isobutyrate, vinyl pivalate, vinyl versatate, vinyl 2-ethylhexanoate, vinyl benzoate and isopropenyl acetate; vinyl chloride; vinyl ether such as methyl vinyl ether, ethyl vinyl ether, n-propyl vinyl ether, n-butyl vinyl ether, i-butyl vinyl ether, t-butyl vinyl ether and phenyl vinyl ether; acrylic ester such as methyl acrylate, ethyl acrylate, n-propyl acrylate, n-butyl acrylate, dodecyl acrylate and phenyl acrylate; methacrylic ester such as methyl methacrylate, ethyl methacrylate, n-propyl methacrylate, n-butyl methacrylate, dodecyl methacrylate and phenyl methacrylate; and acrylonitrile.
In the present invention, polar olefin may be an allyl compound containing a polar group. Examples of an allyl compound containing a polar group include allyl acetate, allyl trifluoroacetate, allyl alcohol, allyl methyl ether, allyl ethyl ether, allyl n-propyl ether, allyl n-butyl ether, allyl t-butyl ether, allyl phenyl ether, allyl chloride, allyl bromide, allylamine, allylamine hydrochloride, N-allylaniline, N-t-butoxycarbonyl-N-allylamine and N-benzyloxycarbonyl-N-allylamine.
In the present invention, polar-olefins may be vinyl ketone monomer. Examples of vinyl ketone include 1-pentadecene-3-one, 1-heptene-3-one, 1-decene-3-one, 3-butene-2-one, 1-nonadecene-3-one, 1-octene-3-one, 1-heptene-3-one, 1-hexene-3-one, 1-pentene-3-one and 1-phenyl-2-propene-1-one.
In the present invention, polar olefins may be N-vinyl monomer. N-vinyl monomer may be selected from N-vinylpyrrolidone, N-vinylcaprolactam, N-vinylformamide; N-vinylacetamide; N-vinylphthalimide; N-methylvinylacetamide; N-vinylcaprolactam; 5-ethyl-5-methyl-3-vinyl-hydantoin; 5 methyl-5-phenyl-3-vinyl-hydantoin; N-vinylcarbazole; N,N-dimethylacrylamide; 5-pentamethylene-3-vinyl-hydantoin and the like.
In the present invention, polar olefin may be polar norbornene monomer, vinylphosphonate, and ester thereof.
Preferred polar olefins in the present inventions are vinyl acetate, vinyl benzoate, acrylonitrile, methyl vinyl ether, ethyl vinyl ether, butyl vinyl ether, allyl acetate, allyl trifluoroacetate, allyl alcohol, allyl methyl ether, allyl ethyl ether, allyl n-propyl ether, allyl n-butyl ether, allyl t-butyl ether, allyl phenyl ether, allyl chloride, allyl bromide, allylamine, allylamine hydrochloride, N-allylaniline, N-t-butoxycarbonyl-N-allylamine and N-benzyloxycarbonyl-N-allylamine.
The method for producing copolymer of non-polar olefins and polar olefins of the present invention can be conducted at a temperature of 30° C. or higher and 150° C. or lower. The polymerization pressure may vary depending on the catalyst component activity and selected non-polar olefins and polar olefins. Typically, a gaseous monomer such as ethylene requires high pressure. Polymerization pressure is 0.50 atmosphere or higher and 200 atmosphere and lower.
Furthermore, the molar ratio of the polar olefin monomer to the organometallic complex in the present invention is 20:1 to 500,000:1. With respect to a gaseous monomer under high pressure, especially at a given pressure such as 400 psi or higher, the molar ratio of the non-polar olefin to the organometallic complex in the present invention may be 5,000,000:1 or higher, for example, 6,000,000:1 or lower, 8,000,000:1 or lower or even higher than that. In the polymerization method of the present invention, the amount of the diluent is 0.0 or higher and 10,000 or less when it is expressed as the diluent volume (ml) per millimole of the organometallic complex of the present invention.
The organometallic compound of the present invention can be used for polymerization by allowing it to be supported on a carrier. There is no particular limitation on the carrier in this case, and examples thereof include inorganic carriers such as silica gel and alumina, and organic carriers such as polystyrene, polyethylene and polypropylene. Examples of the method for supporting a metal complex include a physical adsorption method by impregnating the support with a solution of the metal complex and drying it, and a method of supporting the metal complex by chemically bonding the metal complex and the support.
There is no particular limitation on a polymerization method, and the polymerization can be performed by a generally-used method. That is, a process method such as a solution polymerization method, suspension polymerization method and gas phase polymerization method are available. Particularly preferred are a solution polymerization method and a suspension polymerization method. The polymerization style can be either of batch polymerization or continuous polymerization. Also, the polymerization can be conducted either by single-stage polymerization or multistage polymerization.
The polymerization time can be appropriately adjusted depending on the processing mode and the polymerization activity of the catalyst, and can be as short as several minutes or as long as several thousand hours.
It is preferable to fill the atmosphere in the polymerization system with an inert gas such as nitrogen and argon to prevent components other than monomers such as air, oxygen and moisture being mixed into the atmosphere to retain the catalytic activity. In the case of the solution polymerization, an inert solvent may be used in addition to monomers. There are no particular limitations on the inert solvent, and examples include aliphatic hydrocarbon such as pentane, hexane and heptane; alicyclic hydrocarbon such as cyclopentane, cyclohexane and cycloheptane; aromatic hydrocarbon such as benzene, toluene and xylene; halogenated aliphatic hydrocarbon such as chloroform, methylene chloride, carbon tetrachloride, dichloroethane and tetrachloroethane; halogenated aromatic hydrocarbon such as chlorobenzene, dichlorobenzene and trichlorobenzene; aliphatic ester such as methyl acetate and ethyl acetate; and aromatic ester such as methyl benzoate and ethyl benzoate.
After completion of the polymerization reaction, the (co)polymer as a reaction product is to be isolated by post-treatment using a known operation and treating method (e.g. neutralization, extraction with solvents, washing with water, liquid separation, distillation with solvents and reprecipitation).
EXAMPLES
Hereinafter, the present invention is described in greater detail by referring to Examples described below. The present invention is by no means limited thereto. The measuring methods used in Synthesis Examples, Examples and Comparative Examples are as described below.
[Identification of the Organometallic Compound]
1H-NMR, 13C-NMR and 31P-NMR spectra were measured using nuclear magnetic resonance apparatus (JNM-ECP500 and JNMECS400 manufactured by JEOL Ltd.). The content of the polar monomer unit in the polymer and the branching degree of the copolymer were determined by analyzing 13C-NMR spectrum and adding Cr(acac)3 (acac=Acetylacetonate; CH3COCHCOCH3) as relaxation agent. A molecular weight was calculated by size exclusion chromatography in which polystyrene was employed as an internal standard substance using HLC-8121GPC/HT, manufactured by Tosoh Corporation, provided with TSK gel GMHHR-H(S)HT. The result was adjusted by applying Mark-Houwink parameters for polystyrene (K=1.75×10−2 cm3/g, α=0.67) and linear low-density polyethylene (K=5.90×10−2 cm3/g, α=0.69). The elemental analysis was conducted at Microanalytical Laboratory, Department of Chemistry, Graduate School of Science, the University of Tokyo. The high-resolution mass spectrometry (HRMS) was conducted by the electrospray ionization time-of-flight (ESI-TOF) method using TSK gel JMS-T100LP manufactured by JEOL Ltd. in which polyethylene glycol was employed as an internal standard substance.
Synthesis Examples 1 to 4
The following compounds 1 to 4 were synthesized according to the following scheme 1.




Compound 1: R1=Ph, R2=Ph

Compound 2: R1=Ph, R2=t-Bu

Compound 3: R1=i-Pro, R2=Ph

Compound 4: R1=i-Pro, R2=t-Bu (corresponding to Compound No. 11 in Table I)

Synthesis Example 1
Synthesis of Compound 1 ([methylpalladium(1-diphenylphosphino-2-diphenylphosphinylbenzene)(2,6-lutidine)][hexafluoroantimonate])
As free BPMO (bisphosphine monoxide), after mixing a methylene chloride (2 ml) solution of o-(Ph2P)C6H4(P(O)Ph2)(1-diphyenylphosphino-2-dihenylphosphinylbenzene) (139 mg, 0.301 mmol) and a methylene chloride (2 ml) solution of (cod)PdMeCl (cod=1,5-cyclooctadiene; 80 mg, 0.30 mmol) for five minutes at 25° C., toluene and hexane were added to the mixture to thereby obtain 175 mg of ((o-(Ph2P)C6H4(P(O)Ph2)PdMeCl complex as an intermediate. The solid and 2,6-lutidine (0.033 ml, 0.28 mmol) were dissolved in 5 ml of methylene chloride and reacted with silver hexafluoroantimonate (97 mg, 0.28 mmol) at 25° C. for ten minutes. After removing silver chloride by Celite filtration, solvent was distilled away. The resultant was dissolved in trifluoromethyl benzene and ether was added thereto. The precipitate formed was collected and dried, and recrystallized from methylene chloride to thereby obtain 175 mg of Compound 1 in the paragraph title as a pale orange crystals which were stable in air and in humid condition. The yield was 49%.
1H NMR (CD2Cl2, 500 MHz) δ 7.76-7.70 (m, 2H), 7.61-7.29 (m, 20H), 7.24-7.19 (m, 5H), 3.16 (s, 6H), 0.15 (d, J=3.7 Hz, 3H); 13C-NMR (CD2Cl2, 102 MHz) δ 139.59, 136.73 (dd, J=64, 10 Hz), 134.51 (d, J=12 Hz), 134.05-133.76 (m), 132.60 (d, J=11 Hz), 132.01, 131.45 (d, J=12 Hz), 129.64-129.41 (m), 128.70, 128.46, 128.17, 123.66 (d, J=9 Hz), 26.94, −0.84; 31P NMR (CD2Cl2, 202 MHz) δ 40.42 (d, J=17 Hz), 29.52 (d, J=17 Hz); 19F NMR (CD2Cl2, 470 MHz) δ −113.93-134.61 (m); HRMS-ESI (m/z): [M]+ Calc'd for C38H36NOP2Pd: 690.1307. Found: 690.1313.
Synthesis Example 2
Synthesis of Compound 2 ([methylpalladium(1-diphenylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][hexafluoroantimonate])
Compound 2 was obtained in the same way as in the case of Compound 1 except that o-(Ph2P)C6H4(P(O)t-Bu2) was used as free BPMO. The yield was 57%.
1H NMR (CD2Cl2, 500 MHz) δ 7.82-7.78 (m, 1H), 7.74 (t, J=7.8 Hz, 2H), 7.64 (t, J=7.8 Hz, 1H), 7.58-7.50 (m, 10H), 7.44 (m, 1H), 7.28 (d, J=7.8 Hz, 2H), 3.14 (s, 6H), 1.08 (d, J=14.4 Hz, 18H), 0.16 (d, J=3.0 Hz, 3H); 13C-NMR (CD2Cl2, 102 MHz) δ 158.95, 139.59, 138.38 (dd, J=8.3 Hz), 134.54 (d, J=12 Hz), 134.21-133.28 (m), 132.59 (dd, J=7.3 Hz), 132.01 (d, J=2 Hz), 130.88 (dd, J=12.2 Hz), 130.01, 129.61 (d, J=11 Hz), 129.50, 123.63 (d, J=4 Hz), 37.95 (d, J=58 Hz), 27.26, 27.00, −2.25; 31P NMR (CD2Cl2, 202 MHz) δ 62.36, 35.49; Anal. Calc'd for C34H44F6NOP2PdSb: C, 46.05; H, 5.00; N, 1.58. Found: C, 45.86; H, 5.28; N, 1.37.
Synthesis Example 3
Synthesis of Compound 3 ([methylpalladium(1-diisopropylphosphino-2-diphenylphosphinylbenzene)(2,6-lutidine)][hexafluoroantimonate])
Compound 3 was obtained in the same way as in the case of Compound 1 except that o-(i-Pr2P)C6H4(P(O)Ph2) was used as free BPMO. The yield was 49%.
1H NMR (CD2Cl2, 500 MHz) δ 8.05 (dt, J=7.4, 4.4 Hz, 1H), 7.79 (dt, J=7.6, 0.9 Hz, 1H), 7.72-7.65 (m, 3H), 7.57-7.49 (m, 5H), 7.34-7.29 (m, 4H), 7.25 (dddd, J=15.1, 7.9, 3.4, 1.1 Hz, 1H), 7.14 (d, J=7.8 Hz 2H), 2.66 (s, 6H), 1.41 (dd, J=15.1, 6.9 Hz, 6H), 1.27 (d, J=17.6, 7.1 Hz, 6H), 0.33 (d, J=2.3 Hz, 3H); 13C-NMR (CD2Cl2, 102 MHz) δ 158.99, 139.38, 136.48 (dd, J=15.9 Hz), 134.58 (d, J=10 Hz), 134.73 (dd, J=100, 12.5 Hz), 134.25 (d, J=3 Hz), 133.21 (dd, J=6.3 Hz), 132.91 (d, J=11 Hz), 131.27 (d, J=6 Hz), 131.11, 130.23, 129.73 (d, J=13 Hz), 123.45 (d, J=3 Hz), 27.17 (d, J=26 Hz), 26.27, 19.62 (d, J=4 Hz), 18.86, −6.33 (d, J=4 Hz); 31P NMR (CD2Cl2, 202 MHz) δ 42.74 (d, J=9 Hz), 42.23 (d, J=9 Hz); Anal. Calc'd for C32H40F6NOP2PdSb: C, 44.75; H, 4.69; N, 1.63. Found: C, 44.55; H, 4.69; N, 1.52.
Synthesis Example 4
Synthesis of Compound 4 ([methylpalladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][hexafluoroantimonate])
Compound 4 was obtained in the same way as in the case of Compound 1 except that o-(i-Pr2P)C6H4(P(O)t-Bu2) was used as free BPMO. The yield was 72%.
1H NMR (CD2Cl2, 500 MHz) δ 8.04 (dt, J=7.7 Hz, 3.9 Hz, 1H), 7.80-7.71 (m, 4H), 7.26 (d, J=7.8 Hz, 2H), 3.14 (s, 6H), 2.73-2.65 (m, 2H), 1.35-1.29 (m, 12H), 1.22 (d, J=14.4 Hz, 18H), 0.39 (d, J=2.1 Hz, 3H); 13C-NMR (CDCl3, 102 MHz) δ 158.75, 139.38, 135.20 (d, J=9 Hz), 134.47 (d, J=12 Hz), 133.32-133.11 (m), 132.29 (dd, J=6, 3 Hz), 130.52 (d, J=12 Hz), 123.62 (d, J=3 Hz), 38.27 (d, J=57 Hz), 29.01 (d, J=26 Hz), 27.80, 26.91, 20.13 (d, J=4 Hz), 19.47, −8.11; 31P NMR (CD2Cl2, 202 MHz) δ 58.22, 44.85; Anal. Calc'd for C28H48F6NOP2PdSb: C, 41.07; H, 5.91; N, 1.71. Found: C, 40.90; H, 5.96; N, 1.65.
Synthesis Examples 5 to 6
Next, Compounds 5 to 6 were synthesized according to the following scheme 2.




Compound 5: X=SbF6 (corresponding to Compound No. 206 in Table II)

Compound 6: X=BArF4 (corresponding to Compound No. 262 in Table II)

Compound A (acetanilide palladium chloride dimer) was synthesized according to the method described in a literature (Chem. Eur. J. 2010, 16, 4010-4017).
Synthesis Example 5
Synthesis of Compound 5 ([κ2-(o-acetanilide)palladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene) (2,6-lutidine)][hexafluoroantimonate]
o-(i-Pr2P)C6H4 (P(O)t-Bu2) (142 mg, 0.401 mmol) as free BPMO and Compound A (110 mg, 0.199 mmol) were dissolved in 7 ml of methylene chloride and stirred at 25° C. for three hours. The solution was poured slowly into silver hexafluoroantimonate (0.31 g, 0.90 mmol) in a flask cooled to −78° C. After vigorous stirring at 25° C. for 30 minutes, the resultant solution was condensed by removing silver chloride through Celite filtration. Toluene was poured into the solution to obtain precipitate. The precipitate was recrystallized from methylene chloride to thereby obtain Compound 5 as a pale orange crystals which were stable in air and humid condition. The yield was 73%.
1H NMR (CD2Cl2, 500 MHz) δ 8.96 (s, 1H), 8.00-7.97 (m, 1H), 7.81-7.72 (m, 3H), 7.24 (ddd, J=7.7, 4.7, 1.1 Hz, 1H), 7.09 (t, J=7.1 Hz, 1H), 6.98-6.92 (m, 2H), 2.41 (s, 3H), 1.42 (d, J=14.4 Hz, 18H), 1.22 (dd, J=15.4, 7.1 Hz, 6H), 1.03 (dd, J=18.3, 7.1 Hz, 6H); 13C-NMR (CD2Cl2, 102 MHz) δ 172.55 (d, J=3 Hz), 138.26 (d, J=7 Hz), 135.80 (d, J=9 Hz), 135.12, 134.36 (d, J=11 Hz), 133.35 (dd, J=13.8 Hz), 132.17 (dd, J=6.3 Hz), 131.46 (dd, J=33.4 Hz), 130.73 (dd, J=−12.2 Hz), 126.49, 125.51 (d, J=4 Hz), 125.19 (d, J=2 Hz), 118.50, 38.04 (d, J=57 Hz), 27.83, 27.76 (d, J=24 Hz), 22.49 (d, J=4 Hz), 19.99 (d, J=4 Hz), 19.28; 31P NMR (CD2Cl2, 202 MHz) δ 63.07, 52.30; Anal. Calc'd for C28H44F6NOP2PdSb: C, 40.48; H, 5.34; N, 1.69. Found: C, 40.20; H, 5.41; N, 1.53.
Example 6
Synthesis of Compound 6 ([2-(o-acetanilide)palladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenylborate]
Compound 6 was obtained in the same way as in the case of Compound 5 except that NaBArF4 was used instead of silver hexafluoroantimonate. The yield was 96%.
1H NMR (CD2Cl2, 500 MHz) δ 8.27 (s, 1H), 7.98-7.94 (m, 1H), 7.87-7.69 (m, 11H), 7.56 (s, 4H), 7.26 (ddd, J=7.8, 4.6, 1.1 Hz, 1H), 7.12 (t, J=7.8 Hz, 1H), 7.00 (t, J=7.8 Hz, 1H), 6.82 (dd, J=7.8, 1.4 Hz, 1H), 2.80-2.73 (m, 2H), 2.40 (s, 3H), 1.41 (d, J=14.4 Hz, 18H), 1.21 (dd, J=15.4, 6.9 Hz, 6H), 1.01 (dd, J=18.3, 7.1 Hz, 6H); 13C-NMR (CDCl3, 102 MHz) δ 172.34 (d, J=3 Hz), 162.40 (q, J=50 Hz), 138.59 (d, J=7 Hz), 135.74 (d, J=10 Hz), 135.42, 135.18 (d, J=12 Hz), 134.82, 134.45 (d, J=11 Hz), 133.42 (dd, J=13.8 Hz), 132.21 (dd, J=6.3 Hz), 131.27 (dd, J=34.4 Hz), 130.83 (dd, J=12.2 Hz), 129.51 (qq, J=32.3 Hz), 126.66, 126.02 (d, J=4 Hz), 125.30 (d, J=2 Hz), 125.21 (q, J=272 Hz), 118.15, 38.12 (d, J=58 Hz), 27.80, 27.75 (d, J=25 Hz), 22.88 (d, J=3 Hz), 19.93 (d, J=4 Hz), 19.24; 31P NMR (CD2Cl2, 202 MHz) δ 63.03, 52.65; 19F NMR (CD2Cl2, 470 MHz) δ −62.73; Anal. Calc'd for C60H56BF24NO2P2Pd: C, 49.42; H, 3.87; N, 0.96. Found: C, 49.18; H, 4.09; N, 0.84.
Synthesis Example 7
Synthesis of Compound 7 ([methylpalladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenyl)borate]
Compound 7 was synthesized using Compound 4 as a raw material. That is, a methylene chloride suspension (8 ml) of ([methylpalladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][hexafluoroantimonate) (Compound 4; 0.24 g; 0.30 mmol) and sodium[tetrakis(3,5-bis(trifluoromethyl)phenyl]borate (0.26 g, 0.30 mmol) was stirred at room temperature for 20 minutes under argon atmosphere. The reaction solution was filtered through a pad of Celite (dried diatom) and the filtrate was subjected to vacuum concentration. The yellow solid residue was washed with hexane, and dried under reduced pressure to obtain 0.14 g of Compound 7. The yield was 95%.
1H NMR (CDCl3) δ 7.97 (td, J=7.6, 3.7 Hz, 1H), 7.71 (s, 8H), 7.68-7.59 (m, 4H), 7.51 (s, 4H), 7.17 (d, J=7.5 Hz, 2H), 3.09 (s, 6H), 2.66-2.57 (m, 2H), 1.30-1.25 (m, 12H), 1.16 (d, J=14.5 Hz, 18H), 0.37 (d, J=2.0 Hz, 3H); 31P NMR (202 MHz, CDCl3) δ 58.20, 44.83.
Synthesis Example 8
Synthesis of Compound 7 ([methylpalladium(1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenyl)borate]
Compound 7 was synthesized using Compound 8 represented by the following formula, which is an intermediate in the synthesis of Compound 4 in Synthesis Example 4, as a material.




That is, a methylene chloride suspension (8 ml) of chloromethylpalladium[1-diisopropylphosphino-2-di(t-butyl)phosphinylbenzene] (Compound 8; 0.10 g; 0.20 mmol), sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (0.18 g, 0.20 mmol) and 2,6-dimethylpyridine (0.021 g, 0.20 mmol) was stirred at room temperature for 20 minutes under argon atmosphere. The reaction mixture was filtered through a pad of Celite (dried diatom) and the filtrate was subjected to vacuum concentration. The yellow solid residue was washed with hexane, and dried under reduced pressure to obtain 0.26 g of Compound 7. The yield was 90%. The 1H- and 31P-NMR spectra of Compound 7 were coincident with those described in Synthesis Example 7.

Synthesis Examples 9 to 12
Compounds 9 to 12 were synthesized according to the following reaction scheme.




Synthesis Example 9
Synthesis of Compound 9 (chloromethylpalladium[1-bis(o-methoxyphenyl)phosphino-2-di(t-butyl)phosphinylbenzene])
The reaction solution between the THF solution (14 ml) of 2-bromoanisole (0.34 g, 2.0 mmol) and n-butyllithium (2.1 mmol in 1.64 M pentane solution; 1.3 ml) was added to the THF solution (7 ml) of Compound 9b (0.37 g, 1.0 mmol) synthesized from lithiated di(t-butyl)phenylphosphineoxide and phosphorus trichloride at −78° C. and stirred for 30 minutes under argon atmosphere. After slowly raising the solution temperature to room temperature, the solution was stirred at room temperature for one hour. The reaction was terminated with water, and after subjecting the reaction solution to vacuum concentration, the residue was dissolved in methylene chloride and the resultant solution was filtered through a pad of Celite. After distilling away the solvent, a purification operation was performed through silica gel-column chromatography using methylene chloride/methanol (30:1) as an eluent and recrystallization from THF/hexane to thereby obtain 0.30 g of Compound 9a.
Furthermore, a methylene chloride solution (3 ml) of the obtained Compound 9a (0.14 g, 0.30 mmol) and (cod)PdMeCl (0.088 g, 0.33 mmol) was stirred at room temperature for one hour under argon atmosphere. The reaction solution was filtered through a pad of Celite (dried diatomite) and the filtrate was subjected to vacuum concentration. The residue was subjected to recrystallization from methylene chloride and diethyl ether to obtain 0.15 g of Compound 9. The yield was 81%.
1H NMR (CD2Cl2) δ 8.68 (br s, 1H), 7.65-7.61 (m, 1H), 7.55-7.53 (m, 1H), 7.50-7.48 (m, 3H), 7.40 (dd, J1=J2=7.7 Hz, 1H), 7.14 (dd, J=J2=7.4 Hz, 1H), 6.99 (dd, J=8.2, 5.5 Hz, 1H), 6.89 (dd, J1=J2=7.3 Hz, 1H), 6.80 (dd, J=8.2, 3.4 Hz, 1H), 6.73 (dd, J=11.6, 7.4 Hz, 1H), 3.69 (s, 3H), 3.41 (s, 3H), 1.45 (d, J=14.2 Hz, 9H), 1.09 (d, J=14.2 Hz, 9H), 0.13 (d, J=3.0 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 63.46 (s, P(O)t-Bu2), 27.69 (br s, PAr2).
Synthesis Example 10
Synthesis of Compound 10 ([methylpalladium(1-bis(2-methoxyphenyl)phosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenylborate])
The methylene chloride suspension (2 ml) of Compound 9 (0.050 g, 0.078 mmol), 2,6-dimethylpyridine (0.013 g, 0.12 mmol) and sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (0.069 g, 0.078 mmol) was stirred under argon atmosphere at room temperature for one hour. The reaction solution was filtered through a pad of Celite (dried diatomite) and the filtrate was subjected to vacuum concentration. The residue was subjected to reprecipitation from methylene chloride and pentane to obtain 0.10 g of Compound 10. The yield was 83%.
1H NMR (CD2Cl2) δ 8.30 (dd, J=15.4, 7.8 Hz, 1H), 7.72 (s, 8H), 7.64-7.57 (m, 10H), 7.49 (dd, J=J2=7.7 Hz, 1H), 7.23 (d, J=8.0 Hz, 1H), 7.19 (d, J=7.5 Hz, 1H), 7.14 (dd, J1=J2=7.4 Hz, 1H), 7.06 (dd, J=8.1, 5.6 Hz, 1H), 6.93-6.90 (m, 2H), 6.68 (dd, J=11.7, 7.8 Hz, 1H), 3.76 (s, 3H), 3.49 (s, 3H), 3.18 (s, 3H), 3.04 (s, 3H), 1.05 (d, J=14.2 Hz, 9H), 1.01 (d, J=14.4 Hz, 9H), −0.01 (d, J=3.0 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 63.07 (s, P(O)t-Bu2), 25.90 (s, PAr′2); Anal. Calc'd for C68H60BF24NO3P2Pd: C, 51.88; H, 3.84; N, 0.89. Found: C, 51.69; H, 3.89; N, 0.71.
Synthesis Example 11
Synthesis of Compound 11 (chloromethylpalladium[1-bis(2-methylphenyl)phosphino-2-di(t-butyl)phosphinylbenzene])
Compound 11 was synthesized in a similar manner to that described in Synthesis Example 9. That is, a methylene chloride solution (2 ml) of Compound 11a (0.10 g, 0.22 mmol) synthesized from Compound 9a and (cod)PdMeCl (0.064 g, 0.24 mmol) was stirred at room temperature for one hour under argon atmosphere. The reaction solution was filtered through a pad of Celite (dried diatomite) and the filtrate was subjected to vacuum concentration. The residue was subjected to reprecipitation from methylene chloride and diethyl ether to obtain 0.10 g of Compound 11. The yield was 74%.
1H NMR (CDCl3) δ 7.82-7.78 (m, 1H), 7.63 (dd, J1=J2=7.6 Hz, 1H), 7.51 (dd, J1=J2=7.4 Hz, 1H), 7.42-7.35 (m, 4H), 7.26 (dd, J1=J2=7.9 Hz, 1H), 7.19 (dd, J1=J2=7.2 Hz, 1H), 7.01 (dd, J1=J2=7.6 Hz, 1H), 6.66 (dd, J1=J2=9.4 Hz, 1H), 3.14 (s, 3H), 2.29 (s, 3H), 1.62 (d, J=14.2 Hz, 9H), 1.07 (d, J=14.0 Hz, 9H), 0.54 (d, J=2.7 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 63.07 (s, P(O)t-Bu2), 25.90 (s, PAr2).
Synthesis Example 12
Synthesis of Compound 12 ([methylpalladium(1-bis(2-methylphenyl)phosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenylborate])
Compound 12 was synthesized in a similar manner to that described in Synthesis Example 7. That is, a methylene chloride suspension (3 ml) of Compound 11 (0.082 g, 0.14 mmol), 2,6-dimethylpyridine (0.029 g, 0.27 mmol) and sodium tetrakis[(3,5-bis(trifluoromethyl)phenyl]borate (0.12 g, 0.14 mmol) was stirred at room temperature for 1.5 hour under argon atmosphere. The reaction mixture was filtered through a pad of Celite (dried diatom) and the filtrate was subjected to vacuum concentration. The residue was subjected to reprecipitation from methylene chloride and pentane to obtain 0.19 g of Compound 12. The yield was 90%.
1H NMR (CD2Cl2) δ 7.79-7.46 (m, 21H), 7.32-7.30 (m, 2H), 7.22 (2H, t, J=7.2 Hz), 7.14-7.12 (m, 1H), 6.63 (dd, J=11.3, 8.1 Hz, 1H), 3.12 (s, 3H), 3.09 (s, 3H), 2.94 (s, 3H), 2.28 (s, 3H), 1.04 (d, J=14.4 Hz, 9H), 0.97 (d, J=14.7 Hz, 9H), 0.18 (d, J=2.7 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 64.25 (s, P(O)t-Bu2), 27.37 (s, PAr′2); Anal. Calc'd for C68H60BF24NOP2Pd: C, 52.95; H, 3.92; N, 0.91.
Found: C, 52.57; H, 3.94; N, 0.57.
Synthesis Examples 13 and 14
Compounds 13 and 14 were synthesized according to the following reaction scheme.




Synthesis Example 13
Synthesis of Compound 13 (chloromethylpalladium[1-di(t-butyl)phosphino-2-dimethylphosphinylmethane])
A methylene chloride solution (10 ml) of Compound 13a, which is quantitatively obtained from the reaction of di(t-butyl)phosphinomethyllithium (0.083 g, 0.50 mmol) and dimethylphosphinic chloride (0.083 g, 0.50 mmol), and (cod)PdMeCl (0.13 g, 0.50 mmol) was stirred at room temperature under argon atmosphere. The reaction solution was filtered through a pad of Celite (dried diatomite) and the filtrate was subjected to vacuum concentration. The residue was subjected to purification through recrystallization from methylene chloride and hexane to obtain 0.071 g of Compound 13. The yield was 36%.
1H NMR (CD2Cl2) δ 2.32 (dd, J1=J2=9.7 Hz, 2H), 1.78 (d, J=13.1 Hz, 6H), 1.40 (d, J=14.7 Hz, 18H), 0.88 (d, J=2.3 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 52.40 (d, J=13.1 Hz), 50.83 (d, J=13.1 Hz).
Synthesis Example 14
Synthesis of Compound 14 ([methylpalladium(1-di(t-butyl)phosphino-2-dimethylphosphinylmethane)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenyl)borate])
The methylene chloride suspension (3 ml) of Compound 13 (0.071 g, 0.18 mmol), 2,6-dimethylpyridine (0.019 g, 0.18 mmol) and silver hexafluoroantimonate (0.062 g, 0.18 mmol) was stirred at room temperature under argon atmosphere. After the reaction mixture was filtered through a pad of Celite (dried diatomite), sodium tetrakis(3,5-bis(trifluoromethyl)phenylborate (0.15 g, 0.18 mmol) was added to the filtrate and stirred again at room temperature under argon atmosphere. After the reaction mixture was filtered through a pad of Celite (dried diatomite), the solvent of the filtrate was distilled away to obtain 0.23 g of Compound 14. The yield was 96%.
1H NMR (CD2Cl2) δ 7.74 (s, 8H), 7.66 (t, J=7.7 Hz, 1H), 7.57 (s, 4H), 7.19 (d, J=7.8 Hz, 2H), 2.97 (s, 6H), 2.35 (dd, J1=J2=9.7 Hz, 2H), 1.70 (d, J=12.8 Hz, 6H), 1.45 (d, J=14.9 Hz, 18H), 0.63 (d, J=2.1 Hz, 3H); 31P NMR (C6D6) δ 58.01 (d, J=8.7 Hz), 53.25 (d, J=8.7 Hz).
Synthesis Examples 15 and 16
Compounds 15 and 16 were synthesized according to the following reaction scheme.




Synthesis Example 15
Synthesis of Compound 15 (chloromethylpalladium[1-bis(2,4-dimethoxyphenyl)phosphino-2-di(t-butyl)phosphinylbenzene])
Compound 15 was synthesized in a similar manner to that in Synthesis Examples 9 and 11. That is, the reaction solution between the THF solution (14 ml) of 1-bromo-2,4-dimethoxybenzene (0.43 g, 2.0 mmol) and n-butyllithium (2.1 mmol in 1.64 M pentane solution; 1.3 ml) was added to the THF solution (7 ml) of Compound 9b (0.37 g, 1.0 mmol) synthesized from lithiated di(t-butyl)phenylphosphineoxide and phosphorus trichloride at −78° C. and stirred for 30 minutes under argon atmosphere. After slowly raising the solution temperature to room temperature, the solution was stirred at room temperature for one hour. The reaction was terminated with water, and after subjecting the reaction solution to vacuum concentration, the residue was dissolved in methylene chloride and the resultant solution was filtered through a pad of Celite. After distilling away the solvent, a purification operation was performed through recrystallization from methylene chloride/hexane to thereby obtain 0.40 g of Compound 15a.
Furthermore, a methylene chloride solution (2 ml) of the obtained Compound 15a (0.10 g, 0.18 mmol) and (cod)PdMeCl (0.054 g, 0.20 mmol) was stirred at room temperature for two hours under argon atmosphere. The reaction solution was filtered through a pad of Celite (dried diatomite) and the filtrate was subjected to vacuum concentration. The residue was subjected to purification by recrystallization from methylene chloride/diethyl ether to obtain 0.098 g of Compound 15. The yield from Compound 9b was 55%.
1H NMR (CD2Cl2) δ 8.75 (br s, 1H), 7.62-7.54 (m, 2H), 7.47-7.45 (m, 1H), 7.38 (t, J=7.7 Hz, 1H), 6.68-6.63 (m, 2H), 6.49 (dd, J=4.1, 2.1 Hz, 1H), 6.42 (d, J=8.5 Hz, 1H), 6.31 (t, J=2.3 Hz, 1H), 3.81 (d, J=2.7 Hz, 6H), 3.65-3.63 (3H, m), 3.35 (3H, s), 1.46 (9H, d, J=14.2 Hz), 1.05 (9H, d, J=14.0 Hz), 0.16 (0.5H, d, J=3.2 Hz), 0.11 (2.5H, d, J=3.0 Hz); 31P NMR (202 MHz, CD2Cl2) δ 64.19 (s), 27.17 (br s).
Synthesis Example 16
Synthesis of Compound 16 ([methylpalladium(1-bis(2,4-dimethoxyphenyl)phosphino-2-di(t-butyl)phosphinylbenzene)(2,6-lutidine)][tetrakis(3,5-bis(trifluoromethyl)phenylborate])
Compound 16 was synthesized in a similar manner to that in Synthesis Examples 10 and 12. That is, the methylene chloride suspension (4 ml) of Compound 15 (0.098 g, 0.14 mmol), 2,6-dimethylpyridine (0.023 g, 0.27 mmol) and sodium tetrakis(3,5-bis(trifluoromethyl)phenyl]borate (0.12 g, 0.14 mmol) was stirred at room temperature for 40 minutes under argon atmosphere. The residue was subjected to reprecipitation from methylene chloride and pentane to obtain 0.15 g of Compound 16. The yield was 66%.
1H NMR (CD2Cl2) δ 8.34 (1H, dd, J=15.4, 8.7 Hz), 7.72 (t, J=2.2 Hz, 8H), 7.65-7.52 (m, 8H), 7.47 (dd, J1=J2=7.7 Hz, 1H), 7.20 (d, J=7.6 Hz, 1H), 7.17 (d, J=7.6 Hz, 1H), 6.66 (d, J=8.5 Hz, 1H), 6.62 (dd, J=11.7, 8.5 Hz, 1H), 6.58 (dd, J=4.6, 2.3 Hz, 1H), 6.46 (d, J=8.5 Hz, 1H), 6.40 (dd, J1=J2=2.6 Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.71 (s, 3H), 3.44 (s, 3H), 3.17 (s, 3H), 3.04 (s, 3H), 1.05 (d, J=14.2 Hz, 9H), 1.00 (d, J=14.4 Hz, 9H), −0.02 (d, J=3.0 Hz, 3H); 31P NMR (202 MHz, CD2Cl2) δ 62.79 (s), 24.22 (s).
Homopolymerization of Ethylene
Examples 1 to 9
6.0 μmol (in 1.0 ml of 6.0 M methylene chloride solution) of each of Compounds 1 to 6 (Examples 1-4, 6 and 8) and 0.75 μmol (in 1.0 ml of 0.75 M methylene chloride solution) of each of Compounds 4 to 6 (Examples 5, 7 and 9) were placed in the 50 ml-volume stainless autoclave. After fully drying the autoclave at 120° C., it was cooled to room temperature in a dryer to distil away the methylene chloride under reduced pressure. Toluene (15 ml) was added thereto to solve the catalyst, and ethylene (3 MPa) was injected to allow the solutions to react at 80° C. (or 100° C.) for one hour or three hours. The results are shown in Table 1.












TABLE 1










Molecular






Molecular
weight



Catalyst
Polymerization
Activity
weight (Mn)
distribution



(μmol)
time (h)
(kgmol−1h−1)
(×103)
(Mw/Mn)




















Example 1
Compound 1
3
63
0.8 (1.8)
1.8



(6.0)






Example 2
Compound 2
3
36
16 (38)
2.5



(6.0)






Example 3
Compound 3
1
130
0.9 (1.9)
1.8



(6.0)






Example 4
Compound 4
1
340
39 (91)
2.3



(6.0)






Example 5*1
Compound 4
1
1900
15 (34)
2.6



(0.75)






Example 6*2
Compound 5
1
180
12 (27)
3.6



(6.0)






Example 7*1
Compound 5
1
1300
25 (58)
1.9



(0.75)






Example 8
Compound 6
1
350
39 (92)
2.6



(6.0)






Example 9*1
Compound 6
1
2800
29 (69)
2.1



(0.75)





*1The reaction was performed at 100° C.


*2The reaction was performed in a mixed solution of 1 ml of methylene chloride and 14 ml of toluene instead of using 15 ml of toluene.


*3The value adjusted by applying Mark-Houwink parameters. The values in parentheses are the values in terms of polystyrene before the adjustment.






Table 1 shows that among Compounds 1 to 4, Compound 4, in which both of phosphorus atoms are substituted with a branched alkyl group, gives a high-molecular-weight polymers as well as having very high catalytic activity. Also, according to the quantitative analysis based on 13C-NMR spectrum, the polymer obtained by using Compound 4 had only about one methyl branch per 1,000 carbon atoms, and a highly linear polyethylene was obtained.
Compounds 5 and 6, in which a catalyst precursor had been changed, also showed a very high catalytic activity.
The 13C-NMR spectrum chart of the product in Example 5 is shown in FIG. 1.
Copolymerization of Ethylene and Vinyl Acetate
Example 10
Compound 4, toluene, ethylene (3 MPa) and vinyl acetate in amounts as in Table 2 were put in a stainless steel autoclave to perform a polymerization reaction at a temperature for a period of time as described in the table.
The 13C-NMR spectrum chart of the product in Example 10 is shown in FIG. 2.
Example 11
The catalyst was changed to Compound 6 and the polymerization reaction was performed in a similar manner to that in Example 10 under conditions as described in Table 2.
Although there have been few reports on coordination-insertion polymerization using a comonomer with vinyl acetate, the progress of copolymerization was confirmed in both cases of using Compound 4 and using Compound 6. The result of the quantitative analysis based on 13C-NMR spectrum of the obtained polymer confirmed that a vinyl acetate monomer was incorporated in both terminals of the polymer chain as well as in the main chain.
Copolymerization of Ethylene and Allyl Acetate
Example 12
Compound 4, toluene, ethylene (3 MPa) and allyl acetate in amounts as in Table 2 were put in a stainless steel autoclave to perform a polymerization reaction at a temperature for a period of time as described in the table.
The 13C-NMR spectrum chart of the product in Example 12 is shown in FIG. 3.
Example 13
The catalyst was changed to Compound 6 and the polymerization reaction was performed in a similar manner to that in Example 12 under conditions as described in Table 2.
The progress of copolymerization of ethylene and allyl acetate was confirmed in both cases of using Compound 4 and using Compound 6. The molecular weight (Mn) of the polymer obtained by using Compound 6 was about twice as much as that reported in the case of a catalyst of phosphine-sulfonic acid ester ligand (J. Am. Chem. Soc. 2011, 133, 1232).
Copolymerization of Ethylene and Allyl Chloride
Example 14
Compound 4, toluene, ethylene (3 MPa) and allyl chloride in amounts as in Table 2 were put in a stainless steel autoclave to perform a polymerization reaction at a temperature for a period of time as described in the table. The 13C-NMR spectrum chart of the product in Example 14 is shown in FIG. 4.
Example 15
The catalyst was changed to Compound 6 and the polymerization reaction was performed in a similar manner to that in Example 14 under conditions as described in Table 2.
The progress of copolymerization of ethylene and allyl chloride was confirmed in both cases of using Compound 4 and using Compound 6. The amount of the incorporated polar monomer was nearly equal to that in the above-mentioned report on the catalyst of phosphine-sulfonic acid ester ligands, and the molecular weight (Mn) of the polymer was about twice as much as that in the report.
Copolymerization of Ethylene and Acrylonitrile
Example 16
Compound 4, toluene, ethylene (3 MPa) and acrylonitrile in amounts as in Table 2 were put in a stainless steel autoclave to perform a polymerization reaction at a temperature for a period of time as described in the table. The 13C-NMR spectrum chart of the product in Example 16 is shown in FIG. 5.
Example 17
The catalyst was changed to Compound 6 and the polymerization reaction was performed in a similar manner to that in Example 16 under conditions as described in Table 2.
The progress of copolymerization of ethylene and acrylonitrile was confirmed in both cases of using Compound 4 and using Compound 6. The result of the quantitative analysis based on 13C-NMR spectrum of the obtained polymers confirmed that acrylonitrile monomers were incorporated in both terminals of the polymer chain as well as in the main chain, and the amount of the incorporated monomer was 2.0 to 2.5%.
Copolymerization of Ethylene and Butyl Vinyl Ether
Example 18
Compound 4, toluene, ethylene (3 MPa) and butyl vinyl ether in amounts as in Table 2 were put in a stainless steel autoclave to perform a polymerization reaction at a temperature for a period of time as described in the table. The 13C-NMR spectrum chart of the product in Example 18 is shown in FIG. 6.



















TABLE 2








Comono-
Solvent






Incorpo-
Me


Exam-
Catalyst
Comono-
mer a-
amount
Tempera-
Reaction
Yield
Activity
Mn
Mw
rated a-
branch*4


ples
(mmol)
mer
mount (ml)
(ml)
ture (° C.)
time (h)
(g)
(kgmol−1h−1)
(×103)
(×103)
mount (%)
(/103C)



























10
Compound
Vinyl
12
3
80
15
0.21
0.72
3.4
2.5
1.3
1.5



4 (0.02)
acetate


11
Compound
Vinyl
12
3
80
16
0.18
1.1
3.0
2.5
1.4
1.7



6 (0.01)
acetate


12
Compound
Allyl
3
12
80
12
0.18
1.4
17
2.7
1.0
1.0



4 (0.01)
acetate


13
Compound
Allyl
3
12
80
12
0.94
7.6
35
2.2
1.2
0.7



6 (0.01)
acetate


14
Compound
Allyl
3
12
80
20
0.12
0.31
13
1.9
1.1
1.0



4 (0.02)
chloride


15
Compound
Allyl
3
12
80
20
0.18
0.93
20
2.9
0.7
0.6



6 (0.01)
chloride


16
Compound
Acrylo-
2.5
2.5
100
86
0.50
0.58
3.5
2.4
2.1
1.8



4 (0.01)
nitrile


17
Compound
Acrylo-
2.5
2.5
100
72
0.30
0.69
3.5
2.7
2.5
0.1



6 (0.006)
nitrile


18
Compound
Butyl vinyl
5
10
80
21
0.28
0.66
21
1.9
2.0
1.4



4 (0.02)
ether


19
Compound
Butyl vinyl
5
10
80
20
0.23
1.2
19
2.4
4.1
0.5



6 (0.01)
ether





*4The number of methyl branches per 1,000 carbon atoms in the polymer was determined by the quantitative analysis of 13C NMR spectrum.






Example 19
The catalyst was changed to Compound 6 and the polymerization reaction was performed in a similar manner to that in Example 16 under conditions as described in Table 2.
Although it has been considered the copolymerization of ethylene and vinyl ether is difficult with a conventional cationic α-diimine palladium catalyst, the progress of copolymerization of ethylene and butyl vinyl ether was confirmed in both cases of using Compound 4 and using Compound 6.
Examples 20 to 24
The catalysts in Examples 1 to 9 were changed to Compounds 7, 10, 12 and 14, and homopolyzation of ethylene was conducted in a similar manner. The polymerization conditions and the results are shown in Table 3 and Table 4, respectively.












TABLE 3








Ethylene
Polymerization



Exam-
Catalyst

pressure
temperature
Time


ples
(μmol)
Solvent (ml)
(MPa)
(° C.)
(h)




















20
Compound 7
Toluene (15)
3.0
80
1



(6.0)






21
Compound 7
Toluene (15)
3.0
100
1



(0.75)






22
Compound
Toluene (15)
3.0
100
1



10 (0.75)






23
Compound
Toluene (15)
3.0
100
1



12 (0.75)






24
Compound
Toluene (15)
3.0
80
1



14 (6.0)





















TABLE 4









Number-






Weight-average
average




Yield
Activity
molecular
molecular



Examples
(g)
(kgmol−1h−1)
weight (Mw)
weight (Mn)
Mw/Mn




















20
1.8
300
331,000
138,000
2.4


21
2.0
2,700
166,000
77,000
2.2


22
1.7
2,200
86,000
21,000
4.1


23
0.37
490
160,000
80,000
2.0


24
1.0
168
160,000
57,000
2.8









Examples 25 to 28
The catalysts in Examples 12 and 13 were changed to Compounds 7, 10 and 14, and the copolymerization of ethylene and allyl acetate was conducted in a similar manner, or under conditions in which the ethylene pressure, scale or reaction time was changed. The polymerization conditions and results are shown in Table 5 and Table 6, respectively.













TABLE 5







Allyl

Ethylene





Catalyst
acetate
Toluene
pressure
Polymerization
Time


Examples
(μmol)
(ml)
(ml)
(MPa)
temperature (° C.)
(h)





















25
Compound 7
3
12
3.0
80
12



(10)


26
Compound 7
18.8
56.3
4.0
80
5



(10)


27
Compound 10
3
12
3.0
80
12



(10)


28
Compound 14
3
12
3.0
80
14



(10)






















TABLE 6








Weight-average
Number-average

AAC



Yield
Activity
molecular weight
molecular weight

content


Examples
(g)
(kgmol−1h−1)
(Mw)
(Mn)
Mw/Mn
(mol %)





















25
0.78
6.5
67,000
29,000
2.3
1.2


26
0.52
10
61,000
29,000
2.1
1.2


27
0.35
2.9
24,000
12,000
2.0
1.3


28
0.23
1.6
62,000
22,000
2.8
3.8









Example 29
In the copolymerization of ethylene and allyl acetate using Compound 6 as a catalyst, a scaled up and longtime reaction was performed. That is, Compound 6 (0.029 g, 0.020 mmol), toluene (225 ml) and allyl acetate (75 ml) were added into a 500 ml-volume autoclave, ethylene was filled until the pressure reached 4.0 MPa, and the solution was stirred at 80° C. for 91 hours. After being cooled to room temperature, the reaction solution was added to methanol (1.5 l). The precipitated polymer was collected by filtration and dried under reduced pressure. The yield was 14.9 g and the catalytic activity was calculated to be 8.2 kgmol−1 h−1. As to the molecular weight of the obtained polymer in terms of polystyrene, the weight average molecular weight (Mw), number average molecular weight (Mn) and Mw/Mn were calculated to be 67,000, 32,000 and 2.1, respectively.
Example 30
Homopolyzation of ethylene was conducted using a reaction solution, in which Compound 8 and sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate were reacted in advance, as a catalyst solution. A toluene solution (30 ml) of Compound 8 (5.1 mg, 0.010 mmol) and sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (9.7 mg, 0.011 mmol) was stirred under argon atmosphere at room temperature for 30 minutes and the solution was used as a catalyst solution. At that time, it is assumed that an organometallic compound of formula (II) in which R4 does not exist, i.e.: an organometallic compound represented by the following formula is generated.




Note that, here, a compound corresponding to Compound 8 (R1a=R1b=an isopropyl group, R2a=R2b=a t-butyl group, A1=an orthophenylene group) is described.

Next, the total amount of the catalyst solution and toluene (45 ml) were added into a 120 ml-volume autoclave, and after filling ethylene until the pressure reached 3.0 MPa, the solution was stirred at 80° C. for one hour. After being cooled to room temperature, the reaction solution was added to methanol (300 ml). The precipitated polymer was collected by filtration and dried under reduced pressure. The yield was 5.4 g and the catalytic activity was calculated to be 540 kgmol−1 h−1. As to the molecular weight of the obtained polymer in terms of polystyrene, the weight average molecular weight (Mw), number average molecular weight (Mn) and Mw/Mn were calculated to be 485,000, 211,000 and 2.3, respectively. The amount of the incorporated allyl acetate was calculated to be 1.4 mol % based on the 1H-NMR spectrum using 1,1,2,2-tetrachloroethane-d2 as a solvent.
Example 31
Copolymerization of ethylene and allyl acetate was performed using a catalyst solution prepared in a similar manner to that described in Example 30. That is, a total amount of the catalyst solution obtained by stirring a toluene solution (30 ml) of Compound 8 (5.1 mg, 0.010 mmol) and sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (9.7 mg, 0.011 mmol) at room temperature for 30 minutes; toluene (26.3 ml) and allyl acetate (18.8 ml) were added into a 120 ml-volume autoclave; and after ethylene was filled until the pressure reached 4.0 MPa, the solution was stirred at 80° C. for five hours. After being cooled to room temperature, the reaction solution was added to methanol (300 ml). The precipitated polymer was collected by filtration and dried under reduced pressure. The yield was 0.23 g and the catalytic activity was calculated to be 4.7 kgmol−1 h−1. As to the molecular weight of the obtained polymer in terms of polystyrene, the weight average molecular weight (Mw), number average molecular weight (Mn) and Mw/Mn were calculated to be 58,000, 28,000 and 2.1, respectively. The amount of the incorporated allyl acetate was calculated to be 1.1 mol % based on the 1H-NMR spectrum using 1,1,2,2-tetrachloroethane-d2 as a solvent.
Examples 32 to 37
Homopolymerization of ethylene, copolymerization of ethylene and allyl acetate, copolymerization of ethylene and butyl vinyl ether, and copolymerization of ethylene and methyl acrylate were conducted using Compound 10; Compound 16; and Compound 17 which was synthesized by a similar synthesis method to that of Compound 16. The polymerization conditions and results are shown in Table 7 and Table 8, respectively.













TABLE 7









Ethylene





Catalyst
Polar olefin
Toluene
pressure
Polymerization
Time


Examples
(μmol)
kind (ml)
(ml)
(MPa)
temperature (° C.)
(h)





















32
Compound 16
None
15
3.0
100
1



(0.75)


33
Compound 17
None
15
3.0
80
1



(0.75)


34
Compound 16
Allyl acetate
12
3.0
80
12



(10)
(3)


35
Compound 10
Butyl vinyl
10
3.0
80
26



(10)
ether (5)


36
Compound 16
Butyl vinyl
10
3.0
80
20



(10)
ether (5)


37
Compound 16
Methyl
2.5
3.0
80
15



(10)
acrylate (2.5)






















TABLE 8











Polar





Weight-average
Number-average

monomer



Yield
Activity
molecular weight
molecular weight

content


Examples
(g)
(kgmol−1h−1)
(Mw)
(Mn)
Mw/Mn
(mol %)





















32
1.6
2,200
110,000
37,000
2.9
—


33
0.53
710
270,000
130,000
2.1
—


34
0.18
1.5
20,000
8,900
2.3
0.40


35
0.20
0.76
29,000
13,000
2.2
1.0


36
0.070
0.35
22,000
9,300
2.4
0.6


37
0.040
0.24
15,000
6,900
2.2
8.6









As discussed above, it was confirmed that the novel metal compound of the present invention is very useful as a catalyst for copolymerization of ethylene and various polar monomers. By using a catalyst composition containing the novel metal compound of the present invention, a highly-linear polymer can be obtained and it is possible to obtain a copolymer in which a polar monomer is randomly distributed in a polymer chain. Thus, the catalyst composition of the present invention is industrially very useful because it enables the production of an industrially-useful functionalized polyolefin.

## Claims

1. A method for producing copolymers, comprising a process of reacting non-polar olefins with polar olefins under polymerization conditions in the presence of a catalyst composition containing an organometallic compound,
wherein polar olefins are represented by formula (VII)


CH2═CR13R14  (VII)



wherein R13 represents a hydrogen atom or a methyl group; R14 represents —COOR15, —CN, —OCOR15, —OR15, —CH2—OCOR15, —CH2OH, —CH2—N(R16)2 or —CH2—Hal, wherein R15 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms or an aryl group having 6 to 18 carbon atoms; R16 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an aryl group having 6 to 18 carbon atoms or an alkoxycarbonyl group; and Hal represents a halogen atom, and
wherein the organometallic compound contains bisphosphine monoxide (BPMO) represented by formula (I) and a metal center M comprising elements belonging to Group 10 in the periodic system that forms a complex with BPMO





R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure; and A1 represents an arylene group, a monocyclic heteroarylene group, a bivalent heterocyclic group, an alkylene group having 1 to 2 carbon atoms, a cycloalkylene group having 3 to 10 carbon atoms, an alkenylene group having 2 to 8 carbon atoms, or a cycloalkenylene group having 3 to 10 carbon atoms.

2. The method for producing copolymers as claimed in claim 1, wherein both of R1a and R1b are isopropyl group or t-butyl group.

3. The method for producing copolymers as claimed in claim 1, wherein both of R2a and R2b are t-butyl group.

4. The method for producing copolymers as claimed in claim claim 1, wherein R14 is CH2—OCOR15, CH2OH, —CH2—N(R16)2 or —CH2—Hal.

5. The method for producing copolymers as claimed in claim 1, wherein the organometallic compound is represented by formula (II)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
A1 represents an arylene group, a monocyclic heteroarylene group, a bivalent heterocyclic group, an alkylene group having 1 to 2 carbon atoms, a cycloalkylene group having 3 to 10 carbon atoms, an alkenylene group having 2 to 8 carbon atoms, or a cycloalkenylene group having 3 to 10 carbon atoms;
R3 represents a hydrogen atom, an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms or a bivalent group represented by A2 (A2 represents an arylene group, a monocyclic heteroarylene group, a monocyclic cycloalkylene group, a monocyclic cycloalkenylene group, a monocyclic heterocycloalkylene group, a monocyclic heterocycloalkenylene group, a heterocyclic group or a C2-C4 alkylene group;
R4 represents a neutral electron-donating ligand; R3 and R4 may be crosslinked; when R3 and R4 are crosslinked, L represents a single bond or a bivalent group selected from an alkylene group, a haloalkylene group, an alkenylene group or an alkynylene group; and when R3 and R4 are not crosslinked (that is, when L does not exist), R4 needs not to exist; and
X− represents a counterion of the cationic organometallic compound.

6. The method for producing copolymers as claimed in claim 5, wherein ligand R4 is:
(i) selected from pyridine, a substituted pyridine, a nitrile compound, ammonia, an alkylamine, a substituted alkylamine, an arylamine or a substituted arylamine; or
(ii) represented by formula (1)





(wherein W represents C or S; Z is selected from O, S, NH or NRa (Ra represents an alkyl group or an aryl group) and Y needs not to exist; when Y exists, Y is selected from O, S, NH or NRb (Rb represents an alkyl group or an aryl group); R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, —ORc (Rc represents an alkyl group or an aryl group) or —NRd2 (Rd represents an alkyl group or an aryl group).

7. The method for producing copolymers as claimed in claim 1, wherein the organometallic compound is represented by formula (IIa)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
R6 represents an alkyl group having 1 to 10 carbon atoms, an alkenyl group or an aryl group;
A1 represents an arylene group, a monocyclic heteroarylene group, a bivalent heterocyclic group, an alkylene group having 1 to 2 carbon atoms, a cycloalkylene group having 3 to 10 carbon atoms, an alkenylene group having 2 to 8 carbon atoms, or a cycloalkenylene group having 3 to 10 carbon atoms; and
X− represents a counterion of the cationic organometallic compound.

8. The method for producing copolymers as claimed in claim 7, wherein A1 is a substituted or unsubstituted phenylene group, a substituted or unsubstituted naphthylene group or substituted or an unsubstituted methylene group.

9. The method for producing copolymers as claimed in claim 7, wherein R1a, R1b, R2a and R2b independently represent a branched alkyl group having 3 to 6 carbon atoms.

10. The method for producing copolymers as claimed in claim 7, wherein X— is selected from SbF6−, BPh4−, BArF4− (ArF4 is [3,5-(CF3)2C6H3]4), BF4− or PF6−.

11. The method for producing copolymers as claimed in claim 7, wherein M is palladium.

12. The method for producing copolymers as claimed in claim 1, wherein the organometallic compound is represented by formula (III)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
A1 represents an arylene group, a monocyclic heteroarylene group, a bivalent heterocyclic group, an alkylene group having 1 to 2 carbon atoms, a cycloalkylene group having 3 to 10 carbon atoms, an alkenylene group having 2 to 8 carbon atoms, or a cycloalkenylene group having 3 to 10 carbon atoms;
X− represents a counterion of the cationic organometallic compound;
R6 represents an alkyl group having 1 to 10 carbon atoms, an alkenyl group or an aryl group; R7, R8 and R9 independently represent an alkyl group or an alkoxy group having 1 to 4 carbon atoms.

13. The method for producing copolymers as claimed in claim 12, wherein A1 is a substituted or unsubstituted phenylene group, a substituted or unsubstituted naphthylene group or a substituted or unsubstituted methylene group.

14. The method for producing copolymers as claimed in claim 12, wherein R1a, R1b, R2a and R2b independently represent a branched alkyl group having 3 to 6 carbon atoms.

15. The method for producing copolymers as claimed in claim 12, wherein X− is selected from SbF6−, BPh4−, BArF4− (ArF4 is [3,5-(CF3)2C6H3]4), BF4− and or PF6−.

16. The method for producing copolymers as claimed in claim 12, wherein M is palladium.

17. The method for producing copolymers as claimed in claim 1, wherein the organometallic compound is represented by formula (IV)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
A1 represents an arylene group, a monocyclic heteroarylene group, a bivalent heterocyclic group, an alkylene group having 1 to 2 carbon atoms, a cycloalkylene group having 3 to 10 carbon atoms, an alkenylene group having 2 to 8 carbon atoms, or a cycloalkenylene group having 3 to 10 carbon atoms;
A2 represents an arylene group, a monocyclic heteroarylene group, a monocyclic cycloalkylene group, a monocyclic cycloalkenylene group, a monocyclic heterocycloalkylene group, a monocyclic heterocycloalkenylene group, a heterocyclic group or a C2-C4 alkylene group;
X− represents a counterion of the cationic organometallic compound;
W represents C or S;
Z is selected from O, S, NH or NRa (Ra represents an alkyl group or an aryl group) and Y needs not to exist; when Y exists, Y is selected from O, S, NH or NRb (Rb represents an alkyl group or an aryl group); and
R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, —ORc (Rc represents an alkyl group or an aryl group) or —NRd2 (Rd represents an alkyl group or an aryl group).

18. The method for producing copolymers as claimed in claim 17, wherein the organometallic compound is represented by formula (V)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
A2 represents an arylene group, a monocyclic heteroarylene group, a monocyclic cycloalkylene group, a monocyclic cycloalkenylene group, a monocyclic heterocycloalkylene group, a monocyclic heterocycloalkenylene group, a heterocyclic group or a C2-C4 alkylene group;
R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, —ORc, wherein Rc represents an alkyl group or an aryl group) or —NRd2 and wherein Rd represents an alkyl group or an aryl group;
X− represents a counterion of the cationic organometallic compound; and
R11 may not exist or represents an alkyl group having 1 to 10 carbon atoms, 1 to 4 of which exist on a benzene ring, and the existing two or more R11's may be the same or different with each other.

19. The method for producing copolymers as claimed in claim 18, wherein the organometallic compound is represented by formula (VI)




wherein
M represents an element belonging to Group 10 in the periodic system;
R1a, R1b, R2a and R2b may be the same or different with each other, and independently represent a substituted or unsubstituted alkyl group having 1 to 14 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 14 carbon atoms, a substituted or unsubstituted biphenyl group or a substituted or unsubstituted aryl group; a pair of R1a and R1b and a pair of R2a and R2b may be bonded to form a ring structure;
R5 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, —ORc, wherein Rc represents an alkyl group or an aryl group) or —NRd2 and wherein Rd represents an alkyl group or an aryl group;
R11 may not exist or represents an alkyl group having 1 to 10 carbon atoms, 1 to 4 of which exist on a benzene ring, and the existing two or more R11's may be the same or different with each other; R12 does not exist, or represents an alkyl group having 1 to 10 carbon atoms, which is substituted with an arbitrary replaceable hydrogen in a benzene ring, and when two or more R12 exist, they be the same or different from each other; and
X− represents a counterion of the cationic organometallic compound.

20. The method for producing copolymers as claimed in claim 17, wherein R1a, R1b, R2a and R2b are independently a branched alkyl group having 3 to 14 carbon atoms.

21. The compound method for producing copolymers as claimed in claim 17, wherein X− is selected from SbF6−, BPh4−, BArF4− where ArF4 is [3,5-(CF3)2C6H3]4, BF4− or PF6−.